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Purpose: Plasma cell leukemia (PCL) is a very aggressive and rare hematological 
malignancy that can be distinguished into primary (pPCL), originating de novo, or 
secondary (sPCL), arising as a leukemic transformation of multiple myeloma (MM). 
Genomic and clinical differences between pPCL and MM have been demonstrated, 
mainly based on retrospective studies. This study was aimed at investigating the 
involvement of miRNAs in pPCL and their possible relationship with higher tumor 
aggressiveness. 
Experimental design: MiRNA expression profiles were analyzed in highly-purified 
malignant plasma cells from 18 pPCL cases included in a prospective clinical trial. 
MiRNA expression patterns were evaluated in comparison with a representative series 
of multiple myeloma (MM) patients, in relation to the most recurrent chromosomal 
abnormalities (as assessed by fluorescence in situ hybridization and single nucleotide 
polymorphism-array analysis), and in association with clinical outcome. MiRNA 
expression was also integrated with gene expression profiles and computational 
prediction of miRNA target genes in pPCL and MM samples in order to identify 
putative target genes of deregulated miRNAs. The functional role of a few identified 
miRNAs in plasma cell dyscrasia pathogenesis was explored by transfection of 
synthetic pre/anti-miRNAs in multiple myeloma cell lines. 
Results: We identified a series of deregulated miRNAs in pPCL (42 up- and 41 down-
regulated) in comparison with MM. Some of them, based on their reported functions or 
putative target genes computed by integrative analysis, might have a role in the 
pathobiology of pPCL, such as miR-21, that was found to promote in vitro growth of 
MM cell lines. As regards chromosomal aberrations, the expression of some miRNAs 
mapped to hot-spot altered regions was associated with DNA copy number of the 
corresponding genomic loci; furthermore, TP53 deletion, a frequent cytogenetic lesion 
in our pPCL cohort, was found associated with a trend of down-regulation of miR-34a, 
whose tumor suppressor activity was demonstrated for the first time also in the context 
of MM. Finally, four miRNAs (miR-497, miR-106b, miR-181a* and miR-181b) were 
identified having expression levels correlated with treatment response, and four (miR-
92a, miR-330-3p, miR-22, and miR-146a) with clinical outcome. 
Conclusions: Overall, this study provides insights into the possible contribution of 
miRNAs in the pathogenesis of pPCL and suggests targets for future therapeutic 
investigations.  
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Multistep transformation process from normal to malignant plasma 
cells 
Multiple myeloma (MM) is a genetically complex disease that is becoming more 
common in today’s ageing population. Myeloma belongs to a group of related 
paraproteinaemias that are characterized by an abnormal clonal plasma cell (PC) 
infiltration in the bone marrow (BM) (Greipp et al., 2005; Kyle et al., 2003). Various 
distinct clinical phases of myeloma can be recognized (Table 1, Figure 1), including 
monoclonal gammopathy of undetermined significance (MGUS) and smouldering 
multiple myeloma (SMM; also known as asymptomatic myeloma). Although both of 
these disease phases lack the clinical features of myeloma, they share some of the 
genetic features of myelomas that require treatment (Kyle et al., 2007). By contrast, 
symptomatic multiple myeloma is defined by clinical symptoms and evidence of organ 
damage. A characteristic feature of myeloma cells is the requirement for an intimate 
relationship with the bone marrow microenvironment, where plasma cells are nurtured 
in specialized niches that maintain their long-term survival (Mitsiades et al., 2006). 
However, during the progression of the disease, clonal cells develop the ability to 
proliferate at sites outside of the bone marrow, manifesting as extramedullary myeloma 
(EMM) and plasma cell leukemia (PCL) (Palumbo and Anderson, 2011). These cells 
constitute the end stages in the multistep transformation process from normal to 
malignant plasma cells. Human MM cell lines (HMCLs), which are presumed to 
include most oncogenic events involved in tumor initiation and progression of the 
corresponding tumor, have been generated mainly from a subset of extramedullary MM 
tumors (Kuehl and Bergsagel, 2002). 
Figure 1 | Multi-step molecular pathogenesis of MM. Progression through the different stages of 
multiple myeloma. 
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Multiple Myeloma (MM) 
Multiple myeloma is characterized by the accumulation of terminally differentiated 
clonal PCs in the bone marrow, the production of a monoclonal immunoglobulin (Ig) 
detectable in serum and/or urine and the presence of lytic bone lesions (Gutierrez et al., 
2007). Osteolytic bone lesions and/or compression fractures detected on routine 
radiographs, magnetic resonance imaging (MRI), or computed tomographic (CT) scans 
are the most characteristic markers of end-organ damage in myeloma. Anemia 
(occurring in 70% of patients), renal failure (50%), and hypercalcemia (25%) are the 
other established markers of end-organ damage. The presence of one or more of these 
four markers that is felt to be related to the underlying plasma cell disorder is required 
for the diagnosis of the disease (Table 1) (Rajkumar, 2005). 
Table 1 | Mayo Clinic diagnostic criteria for selected clonal plasma cell disorders. 
Disorder Disease definition 
Monoclonal Gammopathy 
of Undetermined Significance 
(MGUS) 
 Serum monoclonal protein < 3 g/dL 
 Bone-marrow plasma cells < 10% 
 Absence of end-organ damage such as lytic bone lesions, 
anemia, hypercalcemia, or renal failure 
Smoldering Multiple Myeloma (SMM; 
asymptomatic multiple myeloma) 
 Serum monoclonal protein (IgG or IgA) ≥ 3 g/dL and/or 
 Bone-marrow plasma cell ≥ 10% 
 Absence of end-organ damage such as lytic bone lesions, 
anemia, hypercalcemia, or renal failure 
Multiple Myeloma (MM) 
 Bone marrow plasma cells ≥ 10% 
 Presence of serum and/or urinary monoclonal protein (except 
in patients with true non-secretory multiple myeloma) 
 Evidence of lytic bone lesions, anemia, hypercalcemia, or 
renal failure 
MM accounts for about 10% of all hematological cancers (Kyle and Rajkumar, 2004; 
Rajkumar and Kyle, 2005), and its age-adjusted annual incidence in the United States is 
almost 4 per 100,000 (Kyle et al., 2004). MM remains an incurable disease, with a 
median survival being around 3-4 years (ranging from < 1 to > 10 years) and despite 
some evidence for familial clustering, the effects of genetic background and 
environment remain to be clarified (Lynch et al., 2005). 
Cellular origin of myeloma cells 
Post-germinal center (GC) B cells that have undergone productive somatic 
hypermutation, antigen selection, and IgH switching can generate plasmablasts (PBs), 
which typically migrate to the bone marrow microenvironment that enables 
differentiation into long-lived plasma cells (Shapiro-Shelef and Calame, 2005). MM 
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cells are phenotypically similar to PBs/long-lived PCs, including a strong dependence 
on the BM microenvironment for survival and growth (Kuehl and Bergsagel, 2002). 
The immunophenotype of MM cells resembles that of normal, terminally differentiated, 
long-lived BM PC (CD19–CD20–CD45–CD138+). In contrast to normal long-lived PCs, 
MM tumors retain some potential for an extremely low rate of proliferation, usually 
with no more than a few per cent of cycling cells, until advanced stages of MM 
(Rajkumar et al., 1999). 
Genetic architecture and disease progression 
At the cytogenetic level MM genome is complex and more reminiscent of epithelial 
cancers than of more simple leukemias (Morgan et al., 2012). Many of the genetic 
lesions that lead to MM have been defined, and can be categorized as inherited 
variation, translocations, copy number abnormalities, mutations, methylation and 
miRNA abnormalities (Table 2). 
- Chromosomal translocations 
The study of chromosomal translocations that are generated by aberrant class switch 
recombination (CSR) shows that various oncogenes (such as cyclin D1 (CCND1), 
CCND3, fibroblast growth factor receptor 3 (FGFR3), multiple myeloma SET domain 
(MMSET; also known as WHSC1), MAF and MAFB) are placed under the control of the 
strong enhancers of the Ig loci, leading to their deregulation (Bergsagel et al., 2005; 
Gonzalez et al., 2007) (Table 2). Deregulation of the G1/S transition is a key early 
molecular abnormality in myeloma, and the consistent deregulation of a D-group cyclin 
was first noted as a consequence of studying the CSR-driven t(11;14) and t(6;14) 
translocations, which directly deregulate CCND1 and CCND3 respectively (Chesi et 
al., 1996; Shaughnessy, Jr. et al., 2001). Non-translocation-based up-regulation of a D-
group cyclin can also occur, and in the case of t(14;16) this is modulated through MAF, 
which up-regulates CCND2 by binding directly to its promoter (Hurt et al., 2004). 
Cases with t(4;14), which translocates FGFR3 and MMSET at 4p16.3 to the IGH@ 
enhancers, also up-regulates CCND2, but in this case the mechanism is uncertain 
(Bergsagel et al., 2005). The “translocation and cyclin D (TC)” classification is exactly 
based on spiked expression of genes deregulated by primary IgH translocations and the 
universal over-expression of cyclin D genes by either these translocations or another 
mechanism (Bergsagel et al., 2005; Hideshima et al., 2004).  
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Table 2 | Genetic events underlying the initiation and progression of MM to PCL 
(Morgan et al., 2012). 
Primary genetic events (% of tumors) Secondary genetic events (% of tumors) 
IGH@ translocations and genes affected Gains 
• t(4;14): FGFR3 and MMSET (11%) • 1q: CKS1B and ANP32E (40%) 
• t(6;14): CCND3 (< 1%) • 12p: LTBR 
• t(11;14): CCND1 (14%) • 17q: NIK 
• t(14;16): MAF (3%) Secondary translocations 
• t(14;20): MAFB (1.5%) • t(8;14): MYC 
Hyperdiploidy • Other non-IGH@ translocations 
• Trisomies of chr 3, 5, 7, 9, 11, 15, 19 and 21 Epigenetic events 
 • Global hypomethylation (MGUS to MM) 
 • Gene-specific hypermethylation (MM to PCL) 
 Molecular hallmarks 
 • Immortalization 
 
• G1/S abnormality (CDKN2C, RB1 (3%), CCND1 
(3%) and CDKN2A)) 
 
• Proliferation (NRAS (21%), KRAS (28%), BRAF (5%) 
and MYC (1%)) 
 • Resistance to apoptosis (PI3K and AKT) 
 
• NF-κB pathway (TRAF3 (3%), CYLD (3%) and 
I-κB) 
 
• Abnormal localization and bone disease (DKK1, 
FRZB and DNAH5 (8%)) 
 
• Abnormal plasma cell differentiation (XBP1 (3%), 
BLIMP1/PRDM1 (6%) and IRF4 (5%)) 
 
• Abnormal DNA repair (TP53 (6%), MRE11A (1%) 
and PARP1) 
 
• RNA editing (DIS3 (13%), FAM46C (10%) and 
LRRK2 (5%)) 
 
• Epigenetic abnormalities (UTX (10%), MLL (1%), 
MMSET (8%), HOXA9 and KDM6B) 
 • Abnormal immune surveillance 
 
• Abnormal energy metabolism and ADME events 
(absorption, distribution, metabolism and excretion) 
 Deletions 
 • 1p: CDKN2C, FAF1 and FAM46C (30%) 
 • 6q (33%) 
 • 8p (25%) 
 • 11q: BIRC2 and BIRC3 (7%) 
 • 13: RB1 and DIS3 (45%) 
 • 14q: TRAF3 (38%) 
 • 16q: CYLD and WWOX (35%) 
 • 17p: TP53 (8%) 
 
The resultant classification identifies five groups of tumors: TC1 tumors (18%) express 
high levels of either cyclin D1 (11q13) or cyclin D3 (6p21) as a result of an Ig 
translocation; TC2 tumors (37%) ectopically express low to moderate levels of cyclin 
D1 despite the absence of a t(11;14) translocation; TC3 tumors (22%) are a mixture of 
tumors that do not fall into one of the other groups, with most expressing cyclin D2, but 
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a few also expressing low levels of cyclin D1 or cyclin D3; TC4 tumors (16%) express 
high levels of cyclin D2, and also MMSET (and in most cases FGFR3) as a result of a 
t(4;14) translocation; and TC5 tumors (7%) express the highest levels of cyclin D2, and 
also high levels of either MAF or MAFB, consistent with evidence that both MAF 
transcription factors up-regulate the expression of cyclin D2. Other IGH@ 
translocations are seen in myeloma, but in contrast to the CSR-driven events, CSR-
independent translocations tend to occur later in the disease process (Avet-Loiseau et 
al., 2001b; Shou et al., 2000). The gene that is typically deregulated by such events is 
MYC, the deregulation of which may lead to a more aggressive disease phase 
(Nobuyoshi et al., 1991). 
- Copy number abnormalities 
Gains and losses of DNA, resulting in copy number alterations, are common events in 
myeloma (Table 2). The high frequency and recurrent nature of focal loss of copy 
number and loss of heterozygosity (LOH) suggests that the minimal deleted regions 
contain tumor suppressor genes that are driver events leading to the development and 
progression of myeloma (Annunziata et al., 2007; Carrasco et al., 2006; Walker et al., 
2010). Most tumor suppressor genes require the inactivation of both alleles and thus 
have either been identified by the study of homozygous deletions or through the 
integration of mutational analysis with copy number status (Dickens et al., 2010). As 
regards the loss of negative cell cycle regulators, down-regulation of CDKN2C (which 
encodes INK4C) by loss of chromosome 1p32 is important (Dib et al., 2007), as is the 
inactivation of CDKN2A (which encodes INK4A and ARF) by DNA methylation 
(Gonzalez-Paz et al., 2007; Leone et al., 2008). Inactivation of RB1 also affects the 
G1/S checkpoint and may occur as a result of the loss of chromosome 13, which occurs 
in 58% of cases; however, homozygous loss and mutational inactivation of RB1 is 
infrequent (Walker et al., 2010). Other important regions of LOH include 11q (the site 
of the BIRC2 and BIRC3 genes), 16q (the site of CYLD) and 14q32 (the site of TRAF3) 
(Annunziata et al., 2007; Keats et al., 2007). All of these genes are involved in the 
nuclear factor-κB (NF-κB) pathway, indicating that up-regulation of NF-κB signalling 
is important in myeloma. The other major class of recurrent genetic abnormality that is 
seen in myeloma is hyperdiploidy, which is associated with the gain of the odd 
numbered chromosomes, including 3, 5, 7, 9, 11, 15, 19 and 21. Interstitial copy 
number gains that are associated with increased gene expression or with activating 
mutations in oncogenes represent another set of ‘driver’ lesions that can lead to 
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myeloma progression. A classic example of this is the amplification of chromosome 1q, 
which harbours numerous potentially relevant oncogenes (for example, CDC28 protein 
kinase 1B (CKS1B), acidic leucine-rich nuclear phosphoprotein 32 family, member E 
(ANP32E), BCL‑9 and PDZK1) (Walker et al., 2010; Shaughnessy, 2005). Interstitial 
copy number gains that may activate the NF-κB pathway are also seen; these include 
amplification of NIK (also known as MAP3K14), TACI (also known as TNFRSF13B) 
and lymphotoxin beta receptor (LTBR) (Keats et al., 2007). 
- Mutations 
Whole-genome-based and whole-exome-based sequencing strategies have shown that 
there are approximately 35 non-synonymous mutations per myeloma sample (Chapman 
et al., 2011). There are few recurrently mutated genes in MM, that are, for the most 
part, known oncogenes. However, a few novel genes have been identified (such as 
FAM46C in 13% of cases and DIS3 in 11% of cases), and as the numbers of samples 
analyzed increases, the incidence of recurrent genes will undoubtedly rise. This 
observation is consistent with a hypothesis whereby it is the deregulation of pathways 
that is pathogenically important, rather than the deregulation of a specific gene. For 
example, the high frequency of mutations in the ERK pathway (NRAS in 24% of cases, 
KRAS in 27% of cases and BRAF in 4% of cases) indicates that the ERK pathway is 
crucial for myeloma development and points to a treatment strategy that has so far not 
been harnessed. Deregulation of the PI3K pathway is also important in myeloma, 
although it is not frequently mutated (Chapman et al., 2011). 
- Epigenetic changes 
The most important epigenetic change that is relevant to the pathogenesis of myeloma 
is global DNA hypomethylation and gene-specific DNA hypermethylation during the 
transformation of MGUS to myeloma (Walker et al., 2011). The most pronounced 
DNA methylation change is seen in the 15% of patients with the t(4;14) translocation, 
whose myeloma samples have increased gene-specific DNA hypermethylation 
compared with myeloma samples of other cytogenetic subgroups. This t(4;14) 
subgroup over-expresses MMSET, which encodes a histone methyltransferase 
transcriptional repressor (Kim et al., 2008; Marango et al., 2008; Nimura et al., 2009), 
that mediates histone H3 lysine 36 (H3K36) methylation, and its deregulation leads to 
global changes in histone modifications that promote cell survival, cell cycle 
progression and DNA repair (Brito et al., 2009; Kuo et al., 2011; Marango et al., 2008; 
Martinez-Garcia et al., 2011; Pei et al., 2011). Other chromatin modifiers are also 
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deregulated in myeloma, including lysine-specific demethylase 6A (KDM6A; also 
known as UTX), KDM6B, mixed-lineage leukaemia (MLL) and homeobox A9 
(HOXA9), but the full relevance of any resultant chromatin modifications needs further 
validation (Chapman et al., 2011; van Haaften et al., 2009). 
- Other key genetic events 
To date, no consistent mutation of DNA repair genes has been identified in myeloma; 
however, deletions of chromosome 17p occur in 8% of cases at presentation, and this 
frequency increases in the later stages of the disease. The key gene at this site is 
thought to be TP53, and mutations of this gene are associated with increased genomic 
instability and impaired clinical outcomes (Avet-Loiseau et al., 2010; Boyd et al., 
2011; Lode et al., 2010). 
As regards microRNAs, various studies have produced data that suggest a role for 
miRNAs in both normal plasma cell development and in the pathogenesis of myeloma 
(Lionetti et al., 2012). 
Treatment 
The treatment of MM has so far been unrelated to any particular molecular or genetic 
feature. The cornerstones of conventional anti-myeloma therapy have long been 
alkylators and corticosteroids, more specifically oral melphalan and prednisone (MP), 
leading to a median post-treatment overall survival (OS) of 3-4 years. Subsequently, 
high-dose therapy followed by autologous stem cell transplantation (ASCT) has been 
introduced into standard practice as it prolongs survival in comparison with 
conventional chemotherapy (median OS 5–7 years) (Raab et al., 2009; Rajkumar, 
2009). However, over the last few years, the treatment of MM has changed 
considerably as a result of drug development (Raab et al., 2009): in particular, the 
immunomodulatory drugs (IMiDs) thalidomide (Singhal et al., 1999) and lenalidomide 
(Rajkumar et al., 2005; Richardson et al., 2006), and the proteasome inhibitor 
bortezomib (Richardson et al., 2003; Richardson et al., 2005), are effective in treating 
newly diagnosed or relapsed myeloma (Rajkumar, 2009), and have further improved 
overall and event-free survival. However, there is still a lack of effective therapies 
targeting the deregulated biological pathways specifically associated with the disease. 
12 
 
Plasma cell leukemia 
Definition and epidemiology 
PCL is the most aggressive presentation of the PC neoplasms and is characterized by 
circulating PCs > 2×109/L in peripheral blood and a peripheral blood plasmacytosis > 
20% (Albarracin and Fonseca, 2011; Kyle et al., 1974) (Table 3). 
Table 3 | Diagnostic criteria for plasma cell leukemia. 
1. Plasma cells > 2x109/L in peripheral blood 
2. Plasma cells > 20% of blood leukocytes in peripheral blood 
3. Primary plasma cell leukemia (pPCL): presents as de novo leukemia 
4. Secondary plasma cell leukemia (sPCL): progression from a pre-existing multiple myeloma 
International Myeloma Working Group (International Myeloma Working Group, 2003) 
Primary PCL (pPCL) is defined as a malignant PC proliferation first diagnosed in the 
leukemic phase, while secondary PCL (sPCL) corresponds to the leukemic 
transformation of a previously diagnosed multiple myeloma, probably as a consequence 
of clonal transformation (Table 3) (International Myeloma Working Group, 2003; Noel 
and Kyle, 1987). Secondary PCL occurs as a progression of disease in 1 to 4% of all 
cases of MM (Blade and Kyle, 1999). Altogether 60% of all PCL is pPCL (Jimenez-
Zepeda and Dominguez, 2006). In the United States, the incidence is approximately 
0.02 to 0.03 cases per 100,000 population accounting for less than 0.2% of all leukemia 
cases diagnosed from 1997 to 2002 (Yamamoto and Goodman, 2008). As with MM, 
PCL is more common in African Americans than Caucasians (Yamamoto and 
Goodman, 2008). There appears to be a 3:2 male to female sex distribution in both 
primary and secondary PCL (Albarracin and Fonseca, 2011). 
Clinical and pathologic features 
As compared to MM, pPCL tends to be observed in younger individuals. The median 
age of diagnosis of pPCL is 55, a decade younger than the average age of MM 
diagnosis (Tiedemann et al., 2008). The median time to leukemic transformation for 
patients with MM who evolve to sPCL is 21 months (Tiedemann et al., 2008). Patients 
with pPCL present without a MM prodrome, and are characterized by higher 
prevalence of renal insufficiency and elevated β2-microglobulin as opposed to newly 
diagnosed MM. Patients with sPCL are also frequently afflicted with renal 
insufficiency (Tiedemann et al., 2008). In addition to the high number of circulating 
PCs, extramedullary deposits at other sites are common in PCL. For instance up to 15% 
of patients will have hepatomegaly, splenomegaly or lymphadenopathy. An interesting 
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feature of pPCL is that the majority of these individuals do not have clinical evidence 
of overt bone destruction. Osteolytic lesions are more common in sPCL as they are also 
more common in pre-existing MM (sPCL 53% versus pPCL 18%) (Tiedemann et al., 
2008). Because of extensive involvement of the bone marrow, patients with PCL have a 
higher prevalence of anemia and thrombocytopenia (Garcia-Sanz et al., 1999; Noel and 
Kyle, 1987; Tiedemann et al., 2008). Likewise other laboratory parameters of disease 
aggressiveness such as an elevated LDH or β2-microglobulin are common in PCL cases 
(Garcia-Sanz et al., 1999; Tiedemann et al., 2008) (Table 4). 
Table 4 | Clinical and biological differences between PCL and MM (Tiedemann et al., 
2008). 
Characteristic  MM sPCL pPCL P 
Patient number  439 39 41  
Age (years) median 66 65.7 54.5 < 0.001 
Extraosseous plasmacytoma % cases  6 22 0.21 
Osteolytic lesions % cases 81 53 35 0.19 
Splenomegaly % cases  8 18 0.29 
Hepatomegaly % cases  11 32 0.04 
WBC (x109/L) median 5.8 15.7 21.5 0.04 
PB plasmacytosis (%) median 0 52 46 0.017 
PB plasmacytosis (x109/L) median 0 6.3 7.2 0.19 
Hemoglobin (g/dL) median 10.9 9.1 9.4 0.05 
Platelets (x109/L) median 242 53 98 0.05 
Serum creatinine (mg/dL) median 1.2 1.4 1.9 0.03 
Kappa (excl. non-secretors) % cases 66 58 42 0.24 
Lambda (excl. non-secretors) % cases 34 42 58 0.24 
PCLI median 0.4 3.0 1.4 0.47 
BM plasmacytosis % BM 46 63 78 0.11 
WBC: white blood cells; PB: peripheral blood; PCLI: plasma cell labeling index; BM: bone marrow. 
 
 
Genetics of PCL 
- Ploidy 
PCL usually has complex hypodiploid or pseudodiploid karyotypes. In two of the 
largest studies where informative karyotypes were obtained in 34 and 38 patients with 
PCL, most cases were non-hyperdiploid (NH-MM) consisting mostly of complex 
hypodiploid or pseudodiploid karyotypes (67 and 63% respectively) (Avet-Loiseau et 
al., 2001a; Tiedemann et al., 2008). Very few patients with hyperdiploid MM (H-MM) 
karyotypes in PCL have been reported, a finding that contrast with those published in 
MM in which hyperdiploidy is observed in approximately 60% of patients (Blade and 
Kyle, 1999; Taniwaki et al., 1996). 
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- IGH translocations 
Chromosome 14q32 translocations are found in a great number of pPCL and sPCL 
patients (82–87%), as would be expected in NH-MM cases. Based on the study by 
Tiedemann and colleagues, in pPCL IgH translocations almost exclusively involve 
11q13 (CCND1), supporting a central etiological role, while in sPCL multiple partner 
oncogenes are involved, including 11q13, 4p16 (FGFR3/ MMSET) and 16q23 (MAF), 
recapitulating MM (Tiedemann et al., 2008). Avet-Loiseau and colleagues described a 
higher prevalence of t(11;14) and t(14;16) in PCL as compared with a stage III MM 
population (33 and 13% versus 16 and 1%; P = 0.025 and P = 0.002, respectively), 
although in his study the incidence of t(4;14) was identical (12%) (Avet-Loiseau et al., 
2001a). 
Genomic aberrations such as t(4;14), del(13q14), del(17p), del(1p21) and 1q21 gains 
are adverse risk factors in MM but their significance in PCL is unclear (as they usually 
indicate more aggressive behavior which is ubiquitous in PCL) (Avet-Loiseau et al., 
2007; Chang et al., 2007; Chang et al., 2005; Fonseca et al., 2004; Fonseca et al., 2006; 
Shaughnessy, Jr. et al., 2007; Chang et al., 2006; Hanamura et al., 2006). Recently, 
Chang and colleagues investigated 41 PCL cases aiming to detect chromosome 1q 
amplifications and 1p deletions, and compared the genetic aberrations with those in 220 
MM patients (Chang et al., 2009).They report del(17p), del(13q14), del(1p21), 1q21 
amplifications and t(4;14) were more frequent in PCL than MM. Deletions of 1p21 
were associated with 1q21 amplification (P = 0.03) and has a marginal association with 
del(17p) (P = 0.06). They showed patients with 1p21 deletions had a shorter OS than 
those without such deletions (6.2 versus 33.5 months, P = 0.006) (Chang et al., 2009). 
Notably patients with t(4;14) had a shorter survival than those without t(4;14) (1.5 
versus 21.6 months, P = 0.003). The presence of del(13q14), del(17p), t(11;14) and 
1q21 amplification did not influence survival in this cohort. In a multivariate analysis 
adjusting for all above genetic risk factors as well as C-reactive protein, calcium and 
β2-microglobulin levels, only t(4;14) was an independent predictor for a worse OS (P = 
0.008); 1p21 deletions did not retain the prognostic significance (P = 0.14) (Chang et 
al., 2009). 
- Chromosome 13 
In a series of 26 patients Garcia Sanz reported deletion of chromosome 13 in 84% of 
patients with PCL versus 26% for those with MM (Garcia-Sanz et al., 1999). In the 
Mayo study loss of 13q by FISH was found very common in pPCL (85%), more so 
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than in MM (54%) (P = 0.02); but with no difference in prevalence between pPCL and 
sPCL (Tiedemann et al., 2008). As would be expected in NH-MM Avet-Loiseau 
reported a high frequency of monosomy 13 (85%) (Avet-Loiseau et al., 2001a). 
-  Deletions of 17p13 and TP53 inactivation 
Previous studies reported 17p13.1 deletion in MM as a late event found only in 10% of 
patients (Fonseca et al., 2003), and TP53 coding mutations in only 3% (Chng et al., 
2007). In the group of 80 patients reported by Tiedemann there was a prevalence of 
deletion of 17p13.1, causing allelic loss of TP53, in 50% of pPCL and a remarkable 
75% of sPCL. Moreover, functionally relevant TP53 coding mutations were identified 
in 24% of PCL patients tested, contributing to a substantial prevalence of allelic TP53 
inactivation (by mutation or deletion) of 56% in pPCL and 83% in sPCL. Eleven 
percent of pPCL and 33% of sPCL tumors showed biallelic inactivation of TP53 with 
simultaneous allelic deletion and mutation (Tiedemann et al., 2008). Interestingly, 
monoallelic or biallelic inactivation of TP53 did not correlate significantly with 
survival in sPCL, unlike MM, where del(17p13.1) predicts adverse survival (Gertz et 
al., 2005; Lloveras et al., 2004). Lack of correlation between TP53 status and survival 
may reflect ubiquitous targeting of the TP53 pathway in sPCL. 
- MYC abnormalities and RAS mutation 
Rearrangement of MYC was identified by 3′FISH break apart in 33% of pPCL and 
sPCL tumors and was complemented by MYC amplification or 5′MYC translocations in 
8 and 17% of patients, respectively (Tiedemann et al., 2008). MYC rearrangements 
were associated with a trend toward inferior OS in pPCL (median OS of 8.6 versus 27.8 
months without rearrangements, P = 0.006). On the other hand, mutations of K-RAS or 
N-RAS at codons 12, 13 or 61, previously characterized as functionally activating 
(Bezieau et al., 2001; Ahuja et al., 1990; Ortega et al., 2006; Liang et al., 2006), were 
found in 27% pPCL and 15% sPCL (Tiedemann et al., 2008). Activating mutations of 
RAS were associated with a trend toward poorer outcome in pPCL (P = 0.069). 
However, the prevalence of K- or N-RAS mutation in sPCL is comparable to that 
reported in MM (21%) (Ortega et al., 2006), suggesting little, if any, selective pressure 
for RAS activation in secondary leukemic transformation from MM. 
Survival 
PCL is extremely aggressive, associated with short survival (7 to 11 months), with up 
to 28% of patients dying within the first month after diagnosis in different studies 
(Avet-Loiseau et al., 2001a; Noel and Kyle, 1987; Tiedemann et al., 2008). Survival is 
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even shorter when PCL occurs in the context of refractory or relapsing MM. In one of 
the largest series Tiedemann et al. reported an overall survival of 1.3 months for sPCL 
and 11.2 months for pPCL (Tiedemann et al., 2008). Accurate prognostication of PCL 
is hampered by the always low number of cases studied, and the realization that the 
disease is always associated with an adverse outcome. Most studies confirm that 
predictable variables of disease progression predict more aggressive course (Garcia-
Sanz et al., 1999). Garcia-Sanz showed in a very small series that many variables 
predict outcome, all of them associated with greater tumor bulk and cell proliferation 
(Garcia-Sanz et al., 1999). Tiedemann could not find major prognostic implications for 
the various genetic factors tested (Tiedemann et al., 2008). Avet-Loiseau reported 
longer survival, but still limited survival for patients with a t (11;14) (12 months, P = 
0.001) (Avet-Loiseau et al., 2001a), but other series have not reached similar 
conclusions (Fonseca et al., 1998; Lai et al., 1998). 
Treatment of PCL 
Treatment of both pPCL and sPCL, as in MM, is aimed at prolonging survival and 
maximizing quality of life, as there are no recognized curative regimens (Avet-Loiseau 
et al., 2001a; Hayman and Fonseca, 2001). In general, patients are treated with 
aggressive induction therapy followed by ASCT in those who are appropriate 
candidates for this approach. Chemotherapy alone is the principal option for those 
ineligible for ASCT. The best induction regimen for PCL is not known and there is 
great variability in clinical practice. Several combinations that include an alkylating 
agent have been used as sole treatments of PCL or as induction therapy prior to 
anticipated transplant. Combinations that include melphalan are generally avoided as 
induction therapy in potential transplant candidates to allow adequate stem cell 
collection. Most patients need to be treated with the most effective agents currently 
available (Musto et al., 2007; Benson, Jr. and Smith, 2007; Musto et al., 2008) and 
historic data with older agents show poor rates of control. Patients with PCL have had a 
median overall survival of 4 months when treated with melphalan plus prednisone 
(Garcia-Sanz et al., 1999; Tiedemann et al., 2008; Dimopoulos et al., 1994). Multi-
agent infusional chemotherapy (e.g. vincristine, doxorubicin, plus dexamethasone) 
results in a superior, yet still poor median overall survival of approximately 15 to 18 
months (Garcia-Sanz et al., 1999; Tiedemann et al., 2008). Another study reported 
similar results by showing a median OS of 6.8 months for patients treated with VAD 
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(vincristine, doxorubicin and dexamethasone) versus 2 months for those who received 
MP (P < 0.05) (Jimenez-Zepeda and Dominguez, 2006). 
 
MicroRNAs 
MicroRNAs (miRNAs) are small (18-24 nucleotides), evolutionarily conserved non-
coding RNAs that bind to the 3’untranslated region (UTR) of target mRNAs and lead 
to translation repression or mRNA degradation (Ambros, 2004) (Figure 2). 
 
Figure 2 | MiRNA biogenesis (adapted from (Lionetti et al., 2012)). 
 
They are transcribed by RNA polymerase II from genes located in extra- or intragenic 
genomic regions into primary precursors (pri-miRNAs) of different lengths. The 
expression of intronic miRNAs largely coincides with that of their corresponding host 
genes, thus suggesting that they share the same regulatory sequences (Baskerville and 
Bartel, 2005; Kim and Kim, 2007). Pri-miRNAs are processed into secondary 
precursors that have a stem-loop structure (pre-miRNAs) of approximately 70 
nucleotides that are subsequently translocated to the cytoplasm by exportins, where 
they are further processed into 18- to 24-nucleotide duplexes by the RNAase III 
enzyme DICER1. Only one strand (guide strand) is incorporated as mature miRNA into 
the RNA-induced silencing complex (RISC) that mediates target RNA cleavage or 
translational inhibition; the other (passenger) strand is degraded. The RISC leads to 
mRNA cleavage whenever the complementarity between the mature miRNA and the 
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3’UTR of the target mRNA is perfect; when the complementarity is partial, it inhibits 
protein translation. The major component of the RISC is the Argonaute 2 (AGO2) 
protein, which has RNA cleavage activity and is also involved in miRNA biogenesis 
(Tsuchiya et al., 2006). Two thousand and forty-two human miRNA genes are 
currently included in the Sanger miRNA registry (miRBase version 19, August 2012), a 
database of miRNA sequences and annotations. A single miRNA can control the levels 
of hundreds of different target genes, and multiple miRNAs can regulate a single 
mRNA. Various interactions have so far been described, and a number of databases of 
the target genes of each of the known miRNAs are now available (Sethupathy et al., 
2006). Moreover, a very large number of tools have been implemented as means of 
predicting targets based on sequence affinity, thus leading to the predicted interactions 
that represent a strong basis for further in vitro validation (Thomas et al., 2010). There 
is strong evidence indicating that miRNAs play important roles in cell processes such 
as proliferation, development, differentiation and apoptosis (Schickel et al., 2008), and 
it is therefore not surprising that their expression is profoundly deregulated in human 
cancer (Calin and Croce, 2006; Esquela-Kerscher and Slack, 2006). The first direct link 
between miRNAs and cancer was highlighted by Calin et al., who found that the 
minimal deleted region of chromosome 13q14 in chronic lymphocytic leukemia (CLL) 
contained the genes encoding miR-15a and miR-16 (Calin et al., 2002), and that the two 
miRNAs were down-regulated in over two-thirds of the cases. Later, the same Authors 
also demonstrated that the miRNAs target BCL2, an anti-apoptotic oncogene that is 
often over-expressed in CLL (Cimmino et al., 2005). Evidence that miRNAs play a 
causative role in tumorigenesis have accumulated rapidly; transcriptional deregulations, 
epigenetic alterations, mutations, DNA copy number abnormalities, and defects in the 
miRNA biogenesis machinery are all mechanisms contributing to miRNA deregulation 
in cancer, either alone or in combination (Deng et al., 2008). In general terms, the over-
expression of miRNAs targeting one or more tumor suppressor genes (TSG) can inhibit 
anti-oncogenic pathways, whereas miRNAs defects in repressing one or more 
oncogenes may lead to a gain in oncogenic potency. Furthermore, mutations in the 
sequence of mature miRNAs or in the seed-matched sequence of their target mRNAs 
can reduce or eliminate the repression, and switch it towards other transcripts (Ventura 
and Jacks, 2009). The oncogenic role of a number of miRNAs has been experimentally 
demonstrated in various tumors, including hematological malignancies, as is the case of 
the pro-tumorigenic cluster miR-17∼92 (He et al., 2005), miR-155 (Eis et al., 2005), 
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and miR-21 (Chan et al., 2005). Conversely, other miRNAs such as those of let-7 
family have tumor suppressor activity (Johnson et al., 2007; Takamizawa et al., 2004). 
Global miRNA expression profiling studies have revealed miRNA dysregulation in 
virtually all types of cancer and highlighted the usefulness of miRNA profiling in 
diagnosis and prognosis, and in predicting response to therapy (Camps et al., 2008; 
Garzon et al., 2008; Lotterman et al., 2008; Lu et al., 2005; Marcucci et al., 2008; 
Schetter et al., 2008; Yu et al., 2008). 
 
MicroRNAs in plasma cell dyscrasias 
Aberrant miRNA expression in MM has been reported by us and other groups, 
demonstrating that miRNA deregulation characterizes the progression of the disease, 
affects important pathways involved in MM cell survival and reflects the different MM 
genetic subtypes (reviewed in (Lionetti et al., 2012)). Furthermore, data obtained more 
recently in vitro and in vivo provided a proof-of-principle that miRNA-based treatment 
has therapeutic activity in preclinical models of MM and support a framework for 
development of miRNA-based treatment strategies in MM patients (Amodio et al., 
2012; Di Martino et al., 2012). To date, however, no information on miRNA 
expression in pPCL has been reported. 
As stated above, MM is characterized by profound genomic instability involving both 
numerical and structural chromosomal aberrations. Our first main contribution to the 
study of the involvement of miRNAs in myeloma was precisely the identification of 
specific patterns of miRNA expression in different molecular subgroups of the disease. 
In particular, we have provided evidence that the miRNA transcriptional profiles of 40 
MM samples significantly grouped patients according to the proposed TC classification 
(Hideshima et al., 2004), particularly with regard to t(4;14) (TC4) and MAF-
translocated (TC5) samples (gray and red branches in Figure 3, respectively) (Lionetti 
et al., 2009b). 
In a supervised approach, the most striking finding was the highly specific expression 
of three clustered miRNAs (miR-99b, let-7e, and miR-125a-5p) mapping to 19q13.33 in 
the t(4;14) cases (Figure 4). 
 
 Figure 3 | Unsupervised analysis of miRNA expression profiles
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differentiation (Gururajan et al., 2010), thus suggesting a pathogenetic role for miR-
125b associated with impaired expression. Interestingly, none of the miRNAs 
significantly discriminating the TC groups associated with IGH translocations was 
localized in the chromosomal regions specific for the corresponding cytogenetic 
abnormality, which suggests that mechanisms other than those directly deregulating 
gene expression in translocation events may modulate miRNA expression. We are 
currently investigating the role that these miRNAs may have in MM cells, and 
preliminary results have been also produced for the cluster of miR-221 and 222, more 
expressed in TC4 and TC2 patients (hyperdiploid and with high expression of 
CCND2): these miRNAs modulate the expression of p27 protein in MM cells, thus 
influencing directly the entry into S phase of the cell cycle (Figure 5). 
Figure 5 | MiR-221/222 cluster modulates p27 in MM, thereby directly affecting entry into S phase 
(Lionetti et al., 9th Congress of the Italian Society of Experimental Hematology, 2010, Poster#081). (A) 
Expression of p27 protein in U266, KMS34 and KMM1 cell lines transfected with pre-miRs 221 and 222 
(U266 and KMS34), anti-miRs 221 and 222 (KMM1) and relative negative controls. Total cellular 
extracts collected at the indicated time points after transfection were analyzed by Western blotting using 
an anti-p27 antibody, and α-tubulin was included as a control for equal protein loading (B) Flow 
cytometric analysis of U266 cells 72h after transfection with pre-miRs 221 and 222 or relative negative 
control: the analysis showed an increase in pre-miRs transfected cells with an S DNA content. (C) 
Significative negative correlation between P27KIP1 and miR-222 levels in a dataset of 40 primary MM 
patients. The red bars represent mature miRNA expression (vertical axis on right side), and the spots 
represent target gene expression (vertical axis on left side) Horizontal axis: patients samples ordered 
according to increasing P27KIP1 expression. 
In our series of primary tumors the expression of these two miRNAs is anti-correlated 
to that of the messenger of p27, which is an important gene in MM, considering that: 
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the induction of its degradation is the mechanism through which progression through 
the cell cycle is promoted by CKS1B, whose gene is located in the minimal region of 
amplification in 1q21 and whose over-expression is associated with lower survival in 
patients at diagnosis (Chang et al., 2010); and the stabilization of p27 is one of the 
mechanisms through which the proteasome inhibitors decrease the proliferation of 
myeloma cells (Hideshima et al., 2003). Also the integrative analysis defining a 
network of putative functional miRNA-target regulatory relations, which was based on 
computational target prediction and supported by miRNA/mRNA expression data, 
reinforced the suggestion that some of the miRNAs differentially expressed in IGH 
translocated cases may play important roles in the biology of MM PCs. As many as 
five of the seven miRNAs associated with t(4;14) were supposed to target CBFA2T2, a 
nuclear repressor homologous to ETO that binds to the AML1-ETO complex and may 
play a role in hematopoietic differentiation (Fracchiolla et al., 1998; Lindberg et al., 
2005), and let-7e putatively targets PTPRE, a positive regulator of osteoclast function 
and a selective inhibitor of IL-6- and IL-10-induced JAK-STAT signalling (Chiusaroli 
et al., 2004; Tanuma et al., 2001) (Figure 6). 
Figure 6 | Predictive functional regulatory relationships (direct edges) between the miRNAs up-
regulated in t(4;14) cases (green nodes) and their target genes (orange nodes) (Lionetti et al., 
2009b). The network-based frame allows the visualization of possible post-transcriptional co-regulated 
groups of genes and groups of miRNAs sharing one or more target genes. 
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The data generated in our cohort of patients are partially reflected in other MM series 
(Lionetti et al., unpublished results): Figure 7, for example, shows increased expression 
of miR-125a-5p in almost all MM cases of the dataset of the University of Arkansas 
over-expressing MMSET (A) (Gene Expression Ominibus (GEO) Accession Number 
GSE17306) (Zhou et al., 2010), and in MM patients with t(4; 14) of the dataset of 
Salamanca’s group (B) (GEO Accession Number GSE16558) (Gutierrez et al., 2010). 
Figure 7 | MiR-125a-5p over-expression in TC4 MM samples of independent datasets. (A) MMSET 
and miR-125a-5p expression in 52 MM patients profiled on Affymetrix U133 Plus 2.0 GeneChip 
microarrays and Agilent Human miRNA Microarray Platform V1, respectively (Zhou et al., 2010). 
Normalized gene and miRNA expression data were downloaded from NCBI GEO database (Accession 
number GSE17306). (B) MiR-125a-5p expression in 60 MM samples profiled on TaqMan low-density 
arrays (Applied Biosystems) (Gutierrez et al., 2010) and classified according to the occurrence of 
t(4;14); miRNA expression data were downloaded from NCBI GEO database (Accession number 
GSE16558) and expressed as 2-∆Ct after normalization based on the mean expression of RNU44 and 
RNU48.  
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Aim of the study 
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To investigate the involvement of miRNAs in pPCL and their possible relationship 
with higher tumor aggressiveness, miRNA expression profiles were analyzed in highly-
purified malignant plasma cells from 18 pPCL untreated patients included in a 
prospective clinical trial. MiRNA expression patterns were evaluated in comparison 
with a representative series of multiple myeloma (MM) patients, in relation to the most 
recurrent chromosomal abnormalities (as assessed by fluorescence in situ hybridization 
and single nucleotide polymorphism-array analysis), and in association with clinical 
outcome. MiRNA expression was also integrated with gene expression profiles in 
pPCL and MM samples in order to identify putative target genes of deregulated 
miRNAs.  
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Materials and Methods 
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Patient samples 
Bone marrow aspirates from pPCL patients were obtained during standard diagnostic 
procedures. PPCL patients had been diagnosed on the basis of previously described 
criteria (International Myeloma Working Group, 2003; Albarracin and Fonseca, 2011) 
and belonged to a national, multicenter pilot clinical trial including 23 patients (12 
males, 11 females; median age at diagnosis: 60 ys, range: 44-80 ys). This study was 
aimed to evaluate safety and anti-tumor activity of lenalidomide and dexamethasone 
combination in previously untreated pPCL (RV-PCL-PI-350, registered at 
www.clinicaltrials.gov as NCT01553357) (Musto et al., 2011); in particular, enrolled 
patients received lenalidomide at a dose of 25 mg/d for 21 days and oral 
dexamethasone at 40 mg on days 1, 8, 15, and 22 for each 28-day cycle. After 4 cycles, 
responding patients not eligible for ASCT continued until 8 cycles of full-dose LD, if 
tolerated, followed by a maintenance dose of single agent lenalidomide equal to 10 
mg/d on days 1-21 of each 28-day cycle. Patients responding after 4 cycles and eligible 
for ASCT proceeded according to single Centre transplant policy. Patients not 
responding after 4 cycles or progressing during this treatment were considered off-
study. The primary endpoint was the response rate according to International Uniform 
Criteria (van de Donk et al., 2012; Bird et al., 2011); secondary endpoints were safety, 
progression free survival (PFS) and overall survival (OS): for PFS, subjects were 
considered treatment failures at the time of progression or death from any cause; OS 
was defined as time from the date of diagnosis to the date of death or last contact. PFS 
and OS were measured over a median follow-up of 23 months. The description of 
safety, efficacy and side effects of the treatment, together with a comprehensive 
description of the clinical trial, is beyond the scope of this work and will be treated 
elsewhere (Musto et al., manuscript in preparation). All patients gave their informed 
consent for molecular analyses. 
PCs were purified using CD138 immunomagnetic microbeads (MidiMACS, Miltenyi 
Biotec, Auburn, CA). The purity of the positively selected PCs (≥ 90%) was assessed 
by means of flow cytometry. 
High-density single nucleotide polymorphism (SNP)-array analysis 
SNP-array analysis was performed in 17 patients (Table 5 A in the “Results” section). 
MiRNA expression profiling 
MiRNA expression profiling was performed in 18 out of 23 pPCL patients for whom 
material was available (molecular and clinical data of the 18 pPCL patients are reported 
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in Table 5 A in the “Results” section). A series of 39 MM, most of which were 
included in our previous report, were also profiled for global miRNA expression 
(Lionetti et al., 2009b); patients were selected on the basis of their representativeness 
with respect to molecular characteristics. Overall, nine MM patients had t(11;14), seven 
MMs t(4;14), two MMs t(14;16) and one MM t(14;20). The frequencies of the major 
genetic lesions in MM patients were globally consistent with those reported in literature 
(Table 5 B); only del(17p) occurred in a slightly lower percentage (Sawyer, 2011). 
Furthermore, miRNA expression profiling was performed in normal control PCs (NCs) 
obtained from 4 healthy donors. 
Gene expression profiling analysis 
Total RNA was available from 21 pPCL (Table 5 A in the “Results” section) and 36 of 
the 39 MM patients profiled for global miRNA expression. 
Fluorescence in situ hybridization 
Pathological samples from all patients were characterized by fluorescence in situ 
hybridization (FISH) analysis for the presence of the main IGH@ chromosomal 
translocations and for del(13q14), del(17p13), 1p33 (CDKN2C) loss and 1q21.3 
(CKS1B) gain aberrations, as previously described (Agnelli et al., 2009; Fabris et al., 
2005; Fabris et al., 2007). The cut-off levels considered were 10% for fusion or break-
apart probes and 20% for numerical abnormalities, as recommended by the European 
Myeloma Network (EMN) (Ross et al., 2012). 
TP53 mutation analysis 
TP53 mutation analysis was performed on genomic DNA of 17 pPCLs. 
Oligonucleotide primers used to amplify TP53 exons 5–9 and polymerase chain 
reaction (PCR) protocols were downloaded from the IARC TP53 database website 
(http://www-p53.iarc.fr/Download/TP53_DirectSequencing_IARC.pdf). The amplicons 
were sequenced directly with sense and anti-sense primers using the Big Dye 
terminator v1.1 cycle sequencing kit in ABI PRISM 310 automated sequencer (Applied 
Biosystems, FosterCity, CA). 
High-density SNP array analysis 
Total genomic DNA was extracted using Wizard genomic purification DNA kit 
(Promega), then processed and hybridized on Affymetrix GeneChip Human Mapping 
250K NspI arrays following the manufacturer’s protocol (Affymetrix). Each sample 
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was compared with a set of 48 normal Caucasian HapMap references available on the 
Affymetrix web site 
(http://www.affymetrix.com/support/technical/sample_data/500k_data.affx). 
Genotyping Console was used to extract raw DNA copy number (CN) probability from 
CEL files according to Affymetrix guidelines. CN was then estimated using circular 
binary segmentation and normalized on FISH data using DNAcopy and FBN packages 
in R software, respectively, as previously described (Agnelli et al., 2009; Mosca et al., 
2010). Furthermore, DNA CN estimation using CD138 negative bone marrow 
population as normal counterpart (i.e., CD138+ < 0.5% as assessed by FACS analysis) 
was performed in 8 patients. The thresholds for the identification of the gained and lost 
genomic regions resulted as follows: inferred CNs of more than 2.18, 2.52 and 3.41 
corresponded to 3, 4 and 5 or more copies, whereas CNs of less than 1.75 and 1.34 
corresponded to mono- and biallelic deletion. The genotyping data have been deposited 
at NCBI Gene Expression Omnibus repository (http://www.ncbi.nlm.mih.gov/geo) and 
are accessible through GEO Series accession number GSE39383. 
MiRNA expression profiling 
The total RNA extraction and quality assessment were performed as previously 
described (Lionetti et al., 2009a). Samples were profiled using the one-color technique 
in accordance with the manufacturer’s instructions on the Agilent Human miRNA 
Microarray V2 (Agilent Technologies, Santa Clara, CA), which consist of 60-mer DNA 
probes synthesized in situ that represent 723 human and 76 human viral miRNAs from 
the Sanger miRBase (v10.1) (Lionetti et al., 2009b). Expression values were extracted 
according to procedures described in Agilent Feature Extraction Software version 10.1 
manual. Non-human probes, miRNAs flagged as “absent” (i.e. expressed below 
background levels) throughout the whole dataset and miRNAs expired according to 
Sanger miRBase Release 15 (April 2010) were discarded, and quantile normalization 
was applied on raw data using the aroma.light package for Bioconductor. The data 
were then converted to obtain positive values throughout the dataset, at a minimum 
value of 1, and log2 transformed. The raw and normalized miRNA data are available 
through GEO accession number GSE37053. DNAChip Analyzer (dChip) software 
(Schadt et al., 2001) was used to visualize the selected probe list and to generate 
hierarchical agglomerative clustering of the samples, performed using Pearson’s 
correlation coefficient and average linkage as distance and linkage metrics, 
respectively, on those probes whose average change in expression levels varied at least 
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two-fold from the mean across the dataset; the threshold for significance of sample 
enrichment was set at P = 0.0005. Supervised analyses were carried out using samr 
package for Bioconductor. The threshold for significance (at a q-value of 0) was 
determined by tuning the ∆ parameter on the false discovery rate and controlling the q 
value of the selected probe list. Enrichment analysis of miRNA categories was 
performed using TAM (Tool for Annotations of MicroRNAs, V2; 
http://cmbi.bjmu.edu.cn/tam). 
The differentially expressed miRNAs were validated using an independent MM cohort 
(GEO series GSE17306) (Zhou et al., 2010) generated on Agilent Human microRNA 
Microarray V1, including fifty-two MM patients and two healthy donors. To this aim, a 
comprehensive dataset was generated including PC specimens from our pPCL cohort 
and the fifty-two MM samples of the series GSE17306; quantile normalization was 
applied on the expression values of the 276 miRNAs represented on both platforms and 
expressed in at least one sample of our series. All samples passed the relative-log 
expression (RLE) evaluation (namely, the 25th and 75th percentile values required to fall 
between -1 and 1, respectively), made to prevent biases possibly due to inter-cohort 
analysis. Supervised analysis was carried out using the same approach (SAM, q-value = 
0) applied in the proprietary series. 
Gene expression profiling (GEP) analysis 
Preparation of DNA single-stranded sense target, hybridization to GeneChip® Gene 1.0 
ST arrays (Affymetrix Inc., Santa Clara, CA) and scanning of the arrays (7G Scanner, 
Affymetrix Inc.) were performed according to manufacturer’s protocols. Log2-
transformed expression values were extracted from CEL files and normalized using 
NetAffx Transcript Cluster Annotations, Release 32 (June 2011) and robust multi-array 
average (RMA) procedure in Expression Console software (Affymetrix Inc.). Non-
annotated transcript clusters were discarded. The expression values of transcript cluster 
ID specific for loci representing naturally occurring read-through transcriptions or 
mapped to more than one chromosomal location were summarized as median value for 
each sample. The data have been deposited at NCBI Gene Expression Omnibus 
repository (http://www.ncbi.nlm.mih.gov/geo) and are accessible through GEO Series 
accession number GSE39925. The differentially expressed genes between pPCL and 
MM cases were identified using the Significant Analysis of Microarrays software 
version 4.00 as previously described (Agnelli et al., 2007). The functional annotation 
analysis on the selected lists was performed using the Database for Annotation, 
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Visualization and Integrated Discovery (DAVID) 6.7 Tool (U.S. National Institutes of 
Health at http://david.abcc.ncifcrf.gov/). 
Quantitative Real-Time PCR (Q-RT-PCR) 
MicroRNAs. Selected mature miRNAs underwent Q-RT-PCR using TaqMan® 
microRNA assays (Applied Biosystems, Foster City, CA) in accordance with the 
manufacturer’s protocol. All of the RNA samples were normalized on the basis of the 
RNU48 TaqMan® miRNA Assays-Control. The measurement of miRNA expression 
was performed using ABI PRISM 7900HT Sequence Detection System (Applied 
Biosystems). All the samples were run in duplicate. MiRNA expression was relatively 
quantified using the 2-∆Ct method (Applied Biosystems User Bulletin No.2). All the 
samples were run in duplicate. Data were expressed as 2-∆Ct (Applied User Bulletin No. 
2). 
Protein-coding genes. Oligo-dT-primed cDNA was obtained using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). The expression levels of 
selected genes were analyzed in by means of TaqMan Gene Expression Assays and the 
TaqMan Fast Universal Master Mix were used according to manufacturer’s instructions 
(Applied Biosystems, Foster City, CA). GAPDH-specific pre-developed assay reagent 
(PDAR) (Applied Biosystems) was used as internal control. The measurement of gene 
expression was performed using the StepOne Thermocycler (Applied Biosystems). All 
the samples were run in triplicate. Data were expressed as 2-∆∆Ct (Applied User Bulletin 
No. 2). 
DNA copy number/miRNA expression integrative analysis 
To evaluate whether gene dosage effects could be identified for a specific miRNA, the 
relationship between miRNA expression and the inferred CN of the corresponding 
miRNA gene (according to NCBI36/hg18) was measured by means of Kendall’s tau 
test. The analyses were performed using appropriate R software packages. 
Integrative analysis for miRNA target identification 
The integrated analysis of target predictions, miRNA and gene expression data was 
performed using scripts for R software developed in our laboratory. In particular, we 
assessed the correlation between the expression data of all possible miRNA-gene pairs 
in 18 cases of pPCL and 36 cases of MM, and for each significantly anti-correlated pair 
(using Pearson’s correlation coefficient and setting the threshold for Benjamini-
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Hochberg adjusted-P value at 0.05) we verified the existence of a predicted targeting 
relationship by 9 computational algorithms. Specifically, queries were submitted to 
miRecords (http://mirecords.biolead.org) and results were retrieved for the following 
databases: DIANA-microT, RNA22, NBmiRTar, MirTarget2, PicTar, miRanda, and 
RNAhybrid; in addition, updated pre-compiled datasets were downloaded from PITA 
(http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html) and TargetScan 
(http://www.targetscan.org/). Then, we selected those genes predicted as targets by at 
least 5 miRNA target prediction programs. 
3’ UTR Reporter Assay 
293T cells were plated at 600,000 cells per well in a 6 well plate. The next day cells 
were transfected with 30 nM of specific mirVana miRNA mimics (Ambion) or pre-miR 
negative control (Ambion), 3.0 µg of pMir target firefly luciferase reporter plasmid 
containing 3’ UTR sequences from the putative target gene of interest (Origene) and 
0.1 µg of Renilla luciferase expression plasmid pRL-SV40 (Promega) using 
Lipofectamine 2000 (Invitrogen). At 24 hrs post-transfection cells were analyzed using 
the Dual Luciferase Assay Kit (Promega) according to the manufacturer’s instructions. 
Each sample was prepared in triplicate and the entire experiment was repeated twice. 
Survival analysis 
The correlation between the expression levels of each tested miRNA and OS or PFS 
was tested using the Cox proportional hazards model in the globaltest function of R 
software. Patients were stratified into two groups using sliding thresholds on the 
expression levels of the most significant miRNAs identified by globaltest, and the 
groups identified by this approach were then tested for association with survival. 
Survival analysis was conducted with survcomp package in R software, using the 
Kaplan-Meier estimator and log-rank test, and P values were calculated according to 
the standard normal asymptotic distribution. Independence between commonly used 
prognostic factors and miRNA signatures was tested using multivariate Cox regression 
procedure of survival R package. 
Cell lines 
NCI-H929, U266, and SKMM1 MM cell lines were available within our research 
network. RPMI-8226 MM cell line was purchased from Istituto Zooprofilattico 
Sperimentale (I.Z.S.L.E.R.). OPM1, DOX-6, and LR-5 MM cell lines were kindly 
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provided by Dr. Eduard Thomson (University of Texas Medical Branch, Galveston, 
TX, USA), MM1S was purchased by American Type Culture Collection, INA-6 was 
provided by Dr. Renate Burger (University of Erlangen-Nuernberg, Erlangen, Germany 
(Burger et al., 2001; Tassone et al., 2005)). Human BM stromal cells (BMSC) were 
obtained by long-term culture of BM mononuclear cells (Fulciniti et al., 2009; 
Hamasaki et al., 2005; Neri et al., 2007). For co-culture, 1x105 CD138+ cells were 
seeded on 5x104 BMSCs, which had been cultured for 24 to 48 hours in 96-well plates. 
Cells were grown in RPMI medium containing L-glutamine (Gibco®, Life 
Technologies, Carlsbad, CA) with the addition of 10% fetal bovine serum (Lonza 
Group Ltd., Switzerland), 100 U/ml penicillin, and 100 mg/ml streptomycin (Gibco®, 
Life Technologies) at 37°C in a 5% CO2 atmosphere (Tassone et al., 2000; Tassone et 
al., 2002). The IL-6 dependent INA-6 cell line was cultured in the presence of 2.5 
ng/ml of human recombinant IL-6 (Sigma-Aldrich). Methylcellulose colony assays 
were performed in RPMI-1640 medium containing 1.1% methylcellulose (Stem Cell 
Technologies) and 20% FBS. Colony formation was scored at day 14 after plating 2000 
cells (SKMM1) or 1000 cells (RPMI-8226) in 18 well plates containing 1 ml of 
methylcellulose medium. 
In vitro transfection of MM cells with synthetic pre-/anti-miRs 
Synthetic pre- and anti-miRNAs and corresponding negative controls (miR-NC) were 
purchased from Ambion (Applied Biosystems). A total of 1x106 cells were 
electroporated with scrambled (miR-NC) or synthetic pre- or anti-miR at a final 
concentration of 100nmol/L, using Neon Transfection System (Invitrogen) with 1050 
V, 30 ms, 1 pulse. Cell transfection efficiency was evaluated by flow cytometric 
analysis of FAM-dye-labeled synthetic miRNA inhibitor (Invitrogen) transfection. 
Apoptosis analysis 
MM cells transfected with pre/anti-miR or scrambled sequence were harvested and 
treated with Annexin V/7-aminoactinomycin D (7-AAD) solution (BD Pharmingen) at 
24, 48, and 72 hours, according to the manufacturer’s instructions. 
Cell survival and proliferation assays  
For cell viability analysis, 1.5x105 MM cells were plated in 6 well plates, 
electroporated with pre/anti-miR or miR-NC, and then harvested and counted at 24-
hour intervals using a Trypan Blue-excluding viable cells assay. Each sample was run 
34 
 
in triplicate. Alternatively, cell survival was evaluated by MTT assay in 96-well plates. 
In brief, transfected cells were seeded at a density of 1x104 cells per well in 100 µl of 
culture medium. Every 24 hours, 10 µl of 5 mg/ml MTT (Dimethyl thiazolyl diphenyl 
tetrazolium, Sigma) reagent were added to each well, and cells were further incubated 
for 4 h at 37°C. Then medium was removed, and 100 µl of DMSO (dimethyl sulfoxide) 
were added to each well to dissolve the formazan. The optical density (OD) was 
evaluated at wave length of 560 nm. Wells without cells (DMSO alone) were used as 
blank, and experiments were repeated at least three times. Data represent the mean ± 
SD of 3 independent experiments. 
Cell growth was evaluated by BrdU proliferation assay. Electroporated cells were 
incubated for 4 hours in 6 well plates; after harvesting, they were plated in 96 well 
plates for BrdU proliferation assay. Cells were counted at 24 hours intervals. BrdU 
uptake was measured every 24 hours by the DELFIA cell proliferation assay, and 
luminescence was detected using a Victor 4 plate reader (Perkin Elmer. Waltham, 
Massachusetts). Each sample was run at least in triplicate. 
Western blotting 
SDS-PAGE and Western Blotting (WB) were performed according to standard 
protocols. Briefly, cells were lysed in lysis buffer containing 15mM Tris/HCl pH 7.5, 
120mM NaCl, 25mM KCl, 1mM EDTA, 0.5% Triton 100, Halt Protease Inhibitor 
Single-Use cocktail (100X, Thermo Scientific). Whole cells lysates (50 mg per line) 
were separated using 4-12% Novex Bis-Tris SDS-acrylamide gels (Invitrogen), electro-
transferred on Nitrocellulose membranes (Bio-Rad), and immunoblotted with the 
mouse anti-CDK6 (Cell Signaling), anti-Bcl-2, anti-γ-tubulin antibodies (Santa Cruz 
Biotechnology), and the rabbit anti-TP53 antibody (Santa Cruz Biotechnology). 
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Part I 
Chromosomal alterations and miRNA expression profiling in 
pPCL patients 
 
Major cytogenetic aberrations and TP53 mutational analysis of pPCL 
FISH analyses 
The major chromosomal aberrations investigated by FISH in the prospective series of 
23 pPCL patients are reported in Table 5 A. Specifically, translocations at 14q32 
involving IGH@ locus were detected in the large majority of cases (20/23, 87%); 
t(11;14) was the most frequent (9/23, 39.1%), t(14;16) was identified in 7 cases 
(30.4%), and t(4;14) was present in 3 patients (13%). The t(14;20) was present in one 
of 21 investigated cases (4.8%). The t(6;14) was analyzed in 17 cases, all of which 
tested negative. Deletions of chromosome 13q were found in 17 patients (73.9%), 
whereas del(17p13) in 8 patients (34.8%). Alterations of chromosome 1 were analyzed 
in 21 patients: 1p loss was identified in 8 cases (38.1%) and 1q gain in 10 (47.6%); five 
patients showed the concomitant presence of both aberrations. Overall, a contingency 
analysis revealed highly significant inverse correlation between the occurrence of 1q 
gain and of the t(11;14) (adjusted P = 0.006). In agreement with various published 
retrospective pPCL series, consisting of a heterogeneous number of cases (Avet-
Loiseau et al., 2001a; Avet-Loiseau et al., 2012; Chang et al., 2009; Chiecchio et al., 
2009; Tiedemann et al., 2008), in our series we found higher frequencies of t(14;16), 
del(17p), t(11;14) and del(13q) as compared with MM samples, as illustrated in Table 5 
B in comparison with the representative MM cohort profiled here for miRNA 
expression (although statistical significance was not reached for t(11;14) and del(13q). 
TP53 mutation analyses 
We tested the frequency of TP53 mutations in 17 cases (Table 5 A). Four patients 
(4/17, 23.5%) showed a functionally relevant coding mutation in the DNA binding 
domain critical for TP53 tumor-suppressing activity. Three of these cases were also 
positive for 17p deletion and showed a missense mutation at exons 6 (I195T in PCL-
027) and 8 (R280K in PCL-018 and R273C in PCL-030), respectively. The remaining 
TP53-mutated patient (PCL-037) had an in-frame deletion of 6 nucleotides affecting 
codons 155-156 in exon 5.
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Table 5 | Characteristics of patients. (A) Demographic and molecular characteristics of the 23 pPCL patients included in the study. 
Patient Age Sex PP type del (13q)a 
del 
(17p)a 
1q 
gain 
1p 
lossa t(4;14) t(6;14) t(11;14) t(14;16) t(14;20) c-myc 
TP53 
mutation SNP miRNA GEP 
PCL-010 80 M IgGλ - - - - - nd + - - nd nd N N Y 
PCL-014 46 M BJ-λ + + - + - nd + - - nd nd N N Y 
PCL-015 78 M BJ-κ + - + - - - - + - nd wt Y N Y 
PCL-016 57 F IgGκ + - + + - - - + - - wt Yc Y Y 
PCL-017 68 F IgGκ + + + + - - - + - + wt Yc Y Y 
PCL-018 59 F BJ-κ + + - - - - + - - - R280K Yc Y Y 
PCL-019 67 F IgMκ + + + + - - - + - - wt Yc Y Y 
PCL-020 79 F IgGλ - - + - - - - - - - wt Y Y Y 
PCL-021 48 M IgGλ + - + - + - - - - - wt Y Y Y 
PCL-022 50 M IgGκ + + - + - - + - - - nd N Y Y 
PCL-023 60 M IgGκ + + + + - nd - + - nd wt Yc Y Y 
PCL-024 44 M IgDλ + - nd nd - nd - - nd nd nd N N N 
PCL-025 64 F IgGκ - - + + - - - - nd nd nd N N N 
PCL-026 59 M IgGκ + - + - - - - + - + wt Y Y Y 
PCL-027 65 M BJ-λ - + - - - - + - - - I195T Y Y Y 
PCL-028 57 F BJ-κ + - - - - - + - - - wt Yc Y Y 
PCL-029 51 M IgAλ - - - - - - - + - - wt Yc Y Y 
PCL-030 52 F BJ-κ + + - + - - - - + - R273C Yc Y Y 
PCL-032 65 F IgGκ + - + - + - - - - nd wt Y Y Y 
PCL-034 59 F IgGλ + - nd nd + nd - - - nd nd N Y Y 
PCL-035 76 F BJ-κ - - - - - - + - - - wt Y Y Y 
PCL-036 71 M IgGκ + - - - - nd + - - - wt Y Y Y 
PCL-037 72 M IgAλ + - - - - - + - - - 466-471 del6 Y Y Y 
pos/tested    17/23 8/23 10/21 8/21 3/23 0/17 9/23 7/23 1/21 2/15 4/17    
(%)    73.9% 34.8% 47.6% 38.1% 13.0% 0.0% 39.1% 30.4% 4.8% 13.3% 23.5%    
a Only monoallelic deletion. c CD138-negative counterpart available. 
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(B) Characteristics of pPCL patients and MM patients analyzed for miRNA expression (significance of the difference of frequencies between 
pPCL and MM cases analyzed for miRNA expression assessed by Fisher’s exact test; ns: not significant). 
Genetic lesion Frequency in pPCL cases pos/tested (%) 
Frequency in the present MM series 
pos/tested (%) P value 
Frequency in MM according to literature data 
(Sawyer et al., Cancer Genetics 2011) 
del(13q) 17/23 (74%) 22/39 (56%) ns 50% 
del(17p) 8/23 (35%) 2/39 (5%) 0.004 10% 
1q gain 10/21 (48%) 19/37 (51%) ns 40% 
del(1p) 8/21 (38%) na  30%a 
t(11;14) 9/23 (39%) 9/39 (23%) ns 15% 
t(4;14) 3/23 (13%) 7/39 (18%) ns 15% 
t(14;16) 7/23 (30%) 2/39 (5%) 0.01 6-7% 
t(14;20) 1/21 (5%) 1/39 (3%) ns 2% 
aMorgan et al., Nature Reviews Cancer 2012 
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MiRNA expression profiling in pPCL patients 
MiRNA expression profiling was performed in 18 of the 23 pPCL patients included in 
the protocol for which RNA material was available Table 5 A. Two hundred sixty-nine 
miRNAs were detected as expressed above background levels in at least one sample. 
The hierarchical clustering of the samples based on the 46 most variable miRNAs 
across the dataset is reported in Figure 8 A: the groupings appeared unrelated to known 
molecular characteristics as indicated above the heatmap. The supervised three-class 
comparison of miRNA expression between pPCL cases carrying different IGH@ 
chromosomal translocations identified seven differentially expressed miRNAs, of 
which three were associated with t(4;14) (let-7e, miR-135a and miR-148a), three with 
MAF translocations (miR-7, miR-7-1* and miR-454) and one with t(11;14) (miR-342-
3p) (Figure 8 B). Notably, some of these miRNAs had already been found in 
association with specific molecular subgroups in a proprietary dataset of MM patients 
(Lionetti et al., 2009b). 
Regarding numerical chromosomal alterations, gains of the long arm of chromosome 1, 
found in 8 cases, were not associated with the up-regulation of miRNA expression but 
rather with the down-regulation of 5 miRNAs, i.e. let-7b, miR-152, miR-26b, miR-342-
5p and miR-342-3p (Figure 8 C). MiR-342-3p also resulted from the aforementioned 
multiclass analysis: this is compatible with the fact that t(11;14) negative and positive 
cases coincided almost exactly with those carrying or not 1q gain, respectively (as 
indicated by the above-named contingency analysis performed on all pPCL cases 
included in the protocol). Interestingly, a similar pattern was also found in MM patients 
(Lionetti et al., 2009b). Conversely, comparison of miRNA expression between 
patients with or without deletion of 13q or 1p did not identify any differentially 
expressed miRNA at a significant level (data not shown). Patients carrying 
chromosome 17p deletion over-expressed one miRNA (miR-654-5p) at a significant 
level (Figure 8 D). Thus, on the basis of these supervised approaches, we did not 
identify any direct influence of chromosomal gain/deletion on the expression of 
miRNAs involved in each specific alteration. This is in line with what was previously 
observed in our MM dataset, where we were able to highlight a gene-dosage effect only 
through a fine and pointwise correlation of the expression of each miRNA gene with 
the DNA copy number alterations of residing loci (Lionetti et al., 2009b). 
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Figure 8 | MiRNA expression profiles in pPCL patients. (A) Hierarchical clustering of the samples 
using the 46 most variable miRNAs. (B) Heatmap of differentially expressed miRNAs between pPCL 
patients carrying t(4;14), t(11;14), or t(14;16)/t(14;20). Differentially expressed miRNAs were identified 
by means of a SAM three-class analysis. MiRNA expression of the pPCL case (PCL-020) not carrying 
any IGH chromosomal translocation (and therefore not included in the analysis) is also shown. (C) 
Heatmap of differentially expressed miRNAs between pPCL cases carrying or not 1q gain or (D) 
del(17p). In all the heatmaps, patients are in columns, transcripts in rows. The color scale bar represents 
the relative transcript expression changes normalized by the standard deviation, and the color changes in 
each row represent transcript expression relative to the mean across the samples. 
 
Based on the high frequency (7/18) of 17p deletion in our pPCL panel and the known 
involvement of miR-34a in TP53 pathway, in that TP53 induces miR-34 family 
members which in turn target its inhibitor SIRT1, we evaluated the expression of this 
miRNA in relation to this chromosomal lesion. We found that, although at a less 
stringent condition in the supervised analysis, 17p deletion was actually associated with 
 the down-regulation of miR
by Q-RT-PCR analysis 
coefficient between Q-RT
However, based on available GEP data in pPCL samples, 
significantly inversely correlated with that of 
miR-34a regulation was demonstrated to act at a translational level.
TP53 mutations was also available for 
almost all of the patients without any chromosomal alteration of the short arm of 
chromosome 17 did not show
also had a TP53 mutation; 
observed between samples 
only carrying 17p deletion, although
limited number of samples makes it difficult to formulate 
Other miRNAs known to be activated by TP53 but not differentially expressed between 
patients with or without 17p deletion (i.e., other members of 
miR-192, miR-215, miR
samples, with the exception of 
positively or negatively affect the TP53 network, such as, respectively
aforementioned miR-192/215
372/373 (that target LATS2
liver-specific miR-122 
modulating the expression of 
TP53 levels by directly suppressing the TP53 negative regulators p85
and miR-125b, miR-25, miR
-34a (Wilcoxon rank sum test P = 0.0173), as also observed 
in cases for whom material was available (Pearson correlation 
-PCR and microarray expression levels = 0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 | MiR-34a expression in relation to 
deletion of chromosome 17p in pPCL patients. 
Box plot of miR-34a expression as assessed by 
quantitative RT-PCR in pPCL patients with or 
without deletion of chromosome 17p. 
levels are given as 2-∆Ct. 
 
SIRT1 expression was not 
miR-34a, in all likelihood because the 
16 of these patients (Table 5
 any TP53 mutation, while 3 of 6 cases with 17p deletion 
a trend of down-regulation of miR-34a 
carrying both 17p deletion and TP53 mutation and those 
 statistical significance was not reached and
hypotheses.
miR-34
-107) mostly had a very low/undetectable expression in pPCL 
miR-107. Furthermore, other miRNAs are known to 
 (targeting MDM2 and cell cycle regulatory genes)
, involved in a TP53-related positive feedback loop)
(that promotes TP53 stability and transcriptional activity by 
CCNG1), and miR-29 family members (that up
-30d, miR-504 (all directly targeting TP53
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(that can neutralize TP53 activities by targeting multiple critical components of the 
pathway), and miR-155 (counteracting the action of TP53 by inhibiting the expression 
of TP53INP1). Interestingly, with the exception of miR-29 family members, miRNAs 
cooperating with TP53 were absent/poorly expressed, while miR-21 was by far the 
most expressed miRNA, and also miR-25, miR-155, miR-125b and miR-30d were 
among the most highly expressed miRNAs in pPCL patients according to our 
microarray analysis. 
 
In vitro effects of enforced expression of miR-34a in MM cells 
Driven by these data and by the observation reported in the literature of the 
hypermethylation of miR-34a promoter in a small fraction of MM patients and cell 
lines, we decided to investigate the role of this miRNA in MM, in collaboration with 
the group headed by prof.Tassone of the University of Catanzaro, with which our 
laboratory is inserted within a “5X1000” AIRC project, aimed at the identification of 
miRNAs as therapeutic targets in MM and CLL (Di Martino et al., 2012). 
Expression of miR-34a in MM cells 
We first evaluated miR-34a expression in a series of 11 HMCLs by quantitative RT-
PCR. Among these, 2 wild-type TP53 cell lines (MM1S and NCI-H929) showed 
significantly higher miR-34a expression as compared with TP53-mutated HMCLs 
(U266, SKMM1, RPMI-8226, INA-6, DOX6, KMS12-PE, OPM1, OPM2, and LR5; 
Figure 10 A). We next explored if the positive miR-34a-TP53 loop was functional in 
MM cells. Specifically, we treated the TP53 mutated SKMM1 and RPMI-8226 cells, as 
well as the TP53 wild-type NCI-H929 cell line, with nutlin-3, which blocks the TP53-
MDM2 inhibitory interaction and thereby induces the expression of TP53-regulated 
genes (Vassilev et al., 2004). As expected, nutlin-3 treatment induced miR-34a 
expression in TP53 wild-type cells (NCI-H929) but not in TP53-mutated SKMM1 and 
RPMI-8226 cells, as evaluated by q-RT-PCR (P < 0.05, Figure 10 B). Nutlin-3-induced 
up-regulation of miR-34a in turn reduced expression of miR-34a canonical targets, such 
as BCL2 and CDK6 proteins. As expected, this effect was not demonstrable in TP53-
mutated RPMI-8226 cells (Figure 10 C). These findings suggest that miR-34a 
expression is positively modulated by a functional loop in TP53 wild-type MM cells. 
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Figure 10 | MiR-34a expression and nutlin-3 response in 
MM cell lines. (A) Q-RT-PCR analysis of miR-34a in two 
HMCLs bearing wild-type TP53 and nine HMCLs with 
mutated TP53. (B) Q-RT-PCR of miR-34a in nutlin-3-
treated RPMI-8226, SKMM1, and NCI-H929 cells. Values 
represent mean observed in 4 different experiments ± SD. 
(C) Western blotting of BCL2, CDK6, and TP53 protein in 
RPMI-8226 and NCI-H929 cells 24 hours after nutlin-3-
treatment. The protein loading control was γ-tubulin. A 
representative of 3 experiments is shown. 
 
Biological effects of miR-34a transfection in MM cells 
To evaluate the biologic effects of miR-34a, we transfected low-miR-34a MM cell lines 
with synthetic miR-34a or miR-NC (negative control) by electroporation. The anti-
proliferative effect induced by miR-34a in MM cells was evaluated by Trypan Blue 
exclusion assay after synthetic miR-34a or miR-NC transfection. We observed a 
significant growth inhibition in TP53-mutated SKMM1 (P < 0.005, Figure 11 A), 
RPMI-8226 (P < 0.05, Figure 11 B), and OPM1 (P < 0.005, Figure 11 C) MM cells. 
On the other hand, TP53-wild type MM1S and NCI-H929 cells, where a functional 
TP53-miR-34a loop is operative, were not inhibited by miR-34a, although transfection 
of anti-miR-34a oligonucleotides indeed produced a growth stimulus in these cells 
(Figure 11 D and E). These data further confirm miR-34a role as a negative regulator of 
MM cell growth in TP53-wild type cells, and strengthen the rationale of our 
experimental strategy of enforced expression in TP53-mutated MM cells. We next 
investigated the induction of apoptosis by Annexin V/7-AAD assay. An increase of 
apoptotic cell death was observed in TP53-mutated cells following transfection with 
miR-34a, but not with miR-NC, after 48 hours (Figure 11 F and G) that was more 
evident in SKMM1 cells. In contrast, this effect was not observed in TP53-wild-type 
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cells (data not shown). To further explore the anti-MM effects induced by miR-34a, we 
carried out a clonogenic assay to study the colony formation activity of transiently 
transfected cells. We found a 45% and 20% reduced SKMM1 and RPMI-8226 colony 
formation, respectively, 14 days after transfection (Figure 11 H). These findings 
indicate that miR-34a inhibits clonogenic properties of MM cells. 
Figure 11 | MiR-34a has anti-proliferative activity and induces apoptosis in MM cell lines. Average 
± SD values of 3 independent experiments are plotted and P values were calculated by 2-tailed Student t-
test. Cell growth analysis of SKMM1 (A), RPMI-8226 (B), or OPM1 (C) cells transfected with miR-34a 
or NC. P values at 48 and 72 h after transfection are, respectively: 0.01 and 0.005 for SKMM1; 0.001 
and 0.05 for RPMI-8226; 0.006 and 0.008 for OPM1. Significant P values (P < 0.05) are indicated by *. 
Cell growth analysis of MM1S (D) and NCI-H929 (E) cells transfected with miR-34a inhibitor and NC. 
P values: 0.04 and 0.002 for MM1S cells, and 0.04, 0.01, and 0.0008 for NCI-H929 cells at 24, 48, and 
72 h after transfection, respectively. Annexin V/7-AAD analysis of SKMM1 (F) and RPMI-8226 (G) 
cells after transfection with synthetic anti-miR-34a or NC. Results are shown as percentage of apoptotic 
cells. (H) colony formation assay using RPMI-8226 and SKMM1 cells. In all the experiments, P was ≤ 
0.03 comparing miR-34a versus NC. A representative image of miR-34a and NC SKMM1 colonies 
shows homogeneous features of colonies formed by transfected cells with miR-NC, whereas cells 
transfected with miR-34a form irregular heterogeneous colonies. 
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Downregulation of validated miR-34a targets in MM cell lines 
To investigate whether genes known to be regulated by miR-34a were modulated by 
exogenous synthetic mimics, we analyzed BCL2, CDK6, and NOTCH1 mRNA levels 
by q-RT-PCR in miR-34a-transfected SKMM1 and RPMI-8226 cells. As shown in 
Figure 12 A and B, we detected a significant down-regulation of CDK6 and NOTCH1 
mRNA expression 24 hours after cell transfection. This effect occurred together with 
down-modulation of CDK6 and BCL2 proteins evaluated by Western blot analysis 
(Figure 12 C and D). Altogether, these results show that synthetic miR-34a activity 
modulates validated targets. 
Figure 12 | Molecular effects induced by transient expression of miR-34a in MM cells. Q-RT-PCR 
of BCL2, CDK6, and NOTCH1 after transfection with synthetic miR-34a or miR-NC in SKMM1 (A) and 
RPMI-8226 (B) cells. The results are shown as average mRNA expression after normalization with 
GAPDH and ∆∆Ct calculations. Data represent the average ± SD of 3 independent experiments. Western 
blotting of BCL2 and CDK6 protein in SKMM1 (C) and RPMI-8226 (D) cells 24 and 48 hours after 
transfection with synthetic miR-34a or scrambled oligonucleotides (NC). The protein loading control was 
γ-tubulin. Experiments were conducted in triplicate. MiR-34a effects on protein levels reached statistical 
significance (P < 0.05) at all time points.  
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Influence of chromosomal abnormalities on miRNA expression: 
evaluation of dosage effects by means of an integrative genomic 
approach 
The influence on miRNA expression of the allelic imbalances detected at DNA 
genome-wide level was evaluated by performing an integrative analysis of mature 
miRNA expression and the inferred DNA CN values of the corresponding miRNA 
gene/s available for 16 of 18 pPCL cases (Table 5 A). 
SNP-array 
The genome-wide profiles were investigated by SNP-array in the 17 of the 23 pPCL 
cases for whom DNA material was available (Table 5 A). To confirm their estimation 
based on public references, CN were also estimated using DNA from CD138 negative 
BM populations available from eight patients. With the exception of point-wise 
aberrant signals that were discarded from downstream analyses, all the estimated CN 
segments were concordant within ± 0.1 with those obtained comparing the eight tumor 
samples against their normal counterparts (data not shown), suggesting the accuracy of 
the reported results. The analysis allowed the identification of CN alterations (CNA) in 
all cases, showing complete concordance with FISH data. A total of 454 aberrations 
were detected with a median of 20 per sample (range 6-82). Losses were more 
prevalent (273/454 CNAs; 60.1%), including mono- (229/454, 50.4%) or biallelic 
deletions (44/ 454, 9.7%). Of the remaining CNAs, 165 (36.3%) were gains (3 or 4 
copies), and 16 (3.5%) represented amplifications (5 or more copies). Chromosomes 1, 
6, 8, 13, 14, 16, and 17 were the most frequently altered in our series. In particular, 
deletion of 13q was the most frequent alteration (13/17, 76.5%) detected in our dataset, 
with most cases (9/13, 69.2%) showing loss of the entire long arm, while deletions 
involving 17p were found in 6 patients (35%) leading to the definition of two 
minimally altered regions: the larger (2.6 Mb), spanning the 17p13.2-p13.1 region 
including the TP53 gene, and the shorter (0.9 Mb) at 17p12. 
DNA copy number/miRNA expression integrated analysis 
Considering all miRNA genes except those located on chromosome X, the expression 
of 23 miRNAs resulted to be significantly correlated with DNA CN on different 
chromosomes, being chromosome 13 (22%) and the short arm of chromosome 1 the 
most involved (22%) (Table 6 and Figure 13 for a representative example). 
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Table 6 | MiRNAs whose expression in pPCL is significantly positively associated with the 
DNA copy number (CN) of the genomic locus harboring the corresponding gene 
(Kendall’s τ correlation, one-sided P < 0.05). 
miRNA Chromosomal locationa CN = 1, 
n 
CN = 2, 
n 
CN = 3, 
n 
CN = 4, 
n 
CN = 5, 
n 
hsa-miR-197 1p13.3 4 11 1 / / 
hsa-miR-186 1p31.1 3 13 / / / 
hsa-miR-30e 1p34.2 3 12 / 1 / 
hsa-miR-30e* 1p34.2 3 12 / 1 / 
hsa-miR-30c 1p34.2 3 12 / 1 / 
hsa-miR-29c* 1q32.2 / 9 6 / 1 
hsa-miR-28-5p 3q28 1 13 2 / / 
hsa-miR-103 5q35.1 1 13 1 1 / 
hsa-miR-148a 7p15.2 1 13 1 1 / 
hsa-miR-210 11p15.5 / 14 1 1 / 
hsa-miR-483-5p 11p15.5 / 14 1 1 / 
hsa-miR-331-3p 12q22 2 13 / 1 / 
hsa-miR-15a 13q14.3 12 3 1 / / 
hsa-miR-92a 13q31.3 9 6 1 / / 
hsa-miR-19a 13q31.3 9 6 1 / / 
hsa-miR-20a 13q31.3 9 6 1 / / 
hsa-miR-20a* 13q31.3 9 6 1 / / 
hsa-miR-342-3p 14q32.2 3 12 / 1 / 
hsa-miR-630 15q24.1 1 14 / 1 / 
hsa-miR-1225-5p 16p13.3 2 13 / 1 / 
hsa-miR-140-5p 16q22.1 6 8 / 1 1 
hsa-miR-22 17p13.3 5 11 / / / 
hsa-miR-181d 19p13.12 / 13 2 1 / 
aFor miRNAs produced from distinct genomic loci, the expression of the mature miRNA was correlated with the 
DNA CN of each of these genomic locations. The chromosomal location of the genomic locus resulted to be 
associated with mature miRNA expression is indicated, along with the number of pPCL cases having the reported 
inferred DNA copy number of that locus. 
 
 
 
Figure 13 | Representative significant 
correlation between inferred DNA CN 
values of 13q14.3 chromosomal locus 
and miR-15a expression levels in pPCL. 
The bars represent mature miRNA 
expression (right vertical axis), and the 
spots DNA CN values (left vertical axis). 
Horizontal axis: pPCLs by increasing CN 
of 13q14.3. 
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Specifically, we identified miR-15a at 13q14.3 and 4 members of the cluster miR-
17~92 (i.e. miR-19a, miR-20a, miR-20a* and miR-92a) at 13q31.3 on chromosome 13 
(12 and 9 cases showed one copy of the aforementioned genomic loci, respectively), 
and five mature miRNAs (miR-30e, miR-30e*, miR-30c, miR-186 and miR-197) 
encoded by genes mapped to 1p present in single copy in 3 or 4 patients respectively. 
Two miRNAs (miR-210 and miR-483-5p) were encoded by genes mapped to the 
cytoband 11p15.5 which was gained in one patient and present in four copies in a near-
tetraploid case showing the highest expression. Furthermore, CN of chromosome 16 
was correlated with the expression of two miRNAs, miR-140-5p and miR-1225-5p, 
encoded respectively by genes mapped to 16q22.1 (monoallelically deleted in 6 
patients) and 16p13.3 (present in one copy in two samples). We also highlighted mir-
22, mapped to 17p13.3. Interestingly, specific CN/miRNA expression correlations 
found in the present series of pPCLs were previously identified by us in MM patients 
and/or HMCLs: specifically, miR-342-3p at 14q32.2 (whose gene was present in single 
copy in 2 patients and in 4 copies in one patient), miR-20a, miR-20a*, miR-210 and 
miR-140-5p were previously found to have a DNA CN-dependent expression in our 
series of 40 MM samples; miR-15a, miR-19a and miR-22 were identified by applying 
the same approach in a panel of 16 MM cell lines, and the DNA CN of the mir-30e 
gene affected the expression of both mature products (miR-30e and miR-30e*) also in 
cell lines and primary MM cases (Lionetti et al., 2009a; Lionetti et al., 2009b). 
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Part II 
MiRNA expression profiling of pPCL and MM patients 
To determine whether the natural grouping of miRNA expression profiles might 
distinguish PCs from NCs, MM and pPCL, we performed an unsupervised analysis of 
our dataset including 4 NCs, 39 MMs, 18 pPCLs. Based on the 76 most variable 
miRNAs across the dataset, healthy donors represented a clearly distinct transcriptional 
entity, and all pPCL samples were grouped together, along with 8 MM samples (Figure 
14 A); interestingly, all the MM cases carrying t(14;16) or t(14;20) were included in the 
pPCL cluster, whereas all but two of the t(4;14) and two of the t(11;14) MM cases were 
grouped in the MM main cluster. Prompted by these observations, we evaluated in 
pPCL cases the expression of miRNAs previously identified as distinctive of MM TC 
(translocation/cyclin D) groups (Lionetti et al., 2009b); notably, the overall pattern of 
miRNA expression in pPCL was globally similar to that of the TC5 MM molecular 
subgroup, regardless of the presence of MAF translocations (Figure 14 B), with the 
only exception of those miRNAs that strongly discriminated MM TC4 cases (miR-
125a-5p, miR-99b and let-7e, which were found over-expressed also in t(4;14) pPCLs). 
The direct comparison of miRNA expression profiles between pPCL and MM samples 
by supervised analysis identified 42 up-regulated and 41 down-regulated miRNAs in 
the pPCL group (Table 7 and Figure 15 A). 
The up-regulation of miR-155, miR-21, miR-142-3p, miR-142-5p and miR-103 in pPCL 
versus MM patients was confirmed by performing Q-RT-PCR in all samples for which 
RNA was available (11 pPCL and 30 MM patients) (Pearson correlation coefficients 
between Q-RT-PCR and microarray-based expression levels = 0.97, 0.68, 0.65, 0.66 
and 0.68, respectively). 
The TAM enrichment analysis of miRNA categories of the list of 42 up-regulated 
miRNAs identified as most significant (FDR < 15%) the over-representations of four 
classes of miRNAs, namely miRNAs defined as onco-miRNAs or involved in immune 
response, immune system or hematopoiesis (Figure 15 B). No enriched functional 
category was found in the list of the 41 down-regulated miRNAs. 
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Figure 14 | MiRNA expression profiles in NCs, pPCL and MM patients. (A) Dendrogram of the 4 
NCs, 18 pPCL and 39 MM samples clustered according to the expression profiles of the 76 most variable 
miRNAs. Specific characteristics are enriched in colored sub-branches: pink, NC; grey, MM; blue, PCL; 
orange, t(14;16) or t(14;20) samples; green, t(4;14) samples. (B) Heatmap of the 26 miRNAs previously 
identified as distinctive of MM TC groups (Lionetti et al., 2009b) in MM and pPCL patients. MM 
patients are grouped on the basis of TC classification; pPCL samples are ordered according to the IGH 
translocation type.  
A
B
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Table 7 | Differentially expressed miRNAs in pPCL compared with MM samples. 
miRNAa, b SAM scorec miRNAa, b SAM scorec 
hsa-miR-21 7.34 hsa-miR-513b -5.75 
hsa-miR-301a 5.13 hsa-miR-513a-5p -5.35 
hsa-miR-374a 4.98 hsa-miR-494 -4.61 
hsa-miR-330-3p 4.79 hsa-miR-513c -4.47 
hsa-miR-454 4.71 hsa-miR-638 -4.06 
hsa-miR-142-3p 4.68 hsa-miR-193b* -4 
hsa-miR-155* 4.38 hsa-miR-1224-5p -3.61 
hsa-miR-301b 4.29 hsa-miR-193a-5p -3.57 
hsa-miR-140-5p 4.09 hsa-miR-222 -3.5 
hsa-miR-18a 4.03 hsa-miR-145 -3.49 
hsa-miR-99a 3.95 hsa-miR-23a* -3.46 
hsa-miR-590-5p 3.95 hsa-miR-221 -3.4 
hsa-miR-362-3p 3.94 hsa-miR-139-3p -3.37 
hsa-miR-155 3.91 hsa-miR-423-5p -3.13 
hsa-miR-7-1* 3.9 hsa-miR-1226* -3.08 
hsa-miR-21* 3.47 hsa-miR-126 -3.05 
hsa-miR-628-5p 3.32 hsa-miR-1225-5p -3 
hsa-miR-20a* 3.22 hsa-let-7a -2.95 
hsa-miR-18b 3.17 hsa-miR-572 -2.91 
hsa-miR-19a 3.15 hsa-miR-671-5p -2.91 
hsa-miR-29b-1* 3.1 hsa-miR-663 -2.89 
hsa-miR-660 3.07 hsa-miR-765 -2.86 
hsa-miR-424 2.93 hsa-miR-874 -2.84 
hsa-miR-142-5p 2.81 hsa-miR-188-5p -2.8 
hsa-miR-100 2.76 hsa-miR-370 -2.8 
hsa-miR-103 2.59 hsa-miR-636 -2.77 
hsa-miR-532-5p 2.56 hsa-miR-135a* -2.71 
hsa-miR-181d 2.56 hsa-miR-345 -2.68 
hsa-miR-7 2.54 hsa-miR-34c-3p -2.55 
hsa-miR-26b 2.53 hsa-miR-1234 -2.52 
hsa-miR-125b 2.53 hsa-miR-193b -2.47 
hsa-miR-340 2.52 hsa-miR-221* -2.46 
hsa-miR-374b 2.52 hsa-miR-1229 -2.46 
hsa-miR-362-5p 2.49 hsa-miR-877* -2.38 
hsa-miR-20b 2.48 hsa-miR-625* -2.34 
hsa-miR-98 2.46 hsa-miR-324-3p -2.3 
hsa-miR-551b 2.45 hsa-miR-96 -2.21 
hsa-miR-181a* 2.33 hsa-miR-148a -2.19 
hsa-miR-505* 2.3 hsa-miR-483-5p -2.17 
hsa-miR-542-3p 2.27 hsa-miR-1228 -2.16 
hsa-miR-210 2.18 hsa-miR-223 -2.14 
hsa-miR-500* 2.15 
 
a MiRNAs are in bold whose trend of expression from MM to pPCL was significantly maintained 
(Jonckheere-Terpstra test, P < 0.005) when considering the healthy controls. b MiRNAs are in italic if 
differentially expressed between pPCL from proprietary cohort and MM cases from GEO series 
GSE17306. c Up- and down-regulated miRNAs are ordered according to SAM scores. 
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Figure 15 | Differential miRNA expression between pPCL and MM patients (A) Heatmap of the miRNAs identified as differentially expressed between pPCL and 
MM patients. (B) Enriched functions in up-regulated miRNAs in pPCL. The average fold change (FC) in expression level of pPCL versus MM samples is shown for 
each miRNA. MiRNAs are ranked according to their FC. (C) Boxplots of two representative differentially expressed miRNAs maintaining a statistically significant 
trend of differential expression (Jonckheere-Terpstra test, P < 0.005) when considering the healthy controls (NC→MM→pPCL) (miR-125b resulted up-regulated and 
miR-494 down-regulated in pPCL versus MM samples). 
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Validation of miRNA differential expression between pPCL and MM in an 
independent dataset 
The differentially expressed miRNAs between pPCL and MM patients were validated 
using an independent MM cohort (GEO series GSE17306) (Zhou et al., 2010) 
generated on Agilent Human microRNA Microarray V1, including fifty-two MM 
patients and two healthy donors. To this aim, we generated a comprehensive dataset 
including PC specimens from our pPCL cohort and the fifty-two MM samples of the 
series GSE17306; after verifying the absence of biases possibly due to inter-cohort 
analysis, a supervised analysis was carried out using the same approach (SAM, q-value 
= 0) applied in the proprietary series. Notably, when comparing our pPCL cases with 
MM cases of this independent dataset, we found that 41 (80%) of the 51 miRNAs 
belonging to our pPCL miRNA signature and represented on Agilent microRNA 
Microarray V1 showed the same trend of differential expression between pPCL and 
MM (Table 7). 
Modulation of miRNAs included in MM-pPCL signature throughout progression 
from normal plasma cells to PCL 
In addition, based on the hypothesis that the deregulation of these miRNAs might be 
compatible with the “strength” of neoplastic transformation, we investigated whether 
among the 83 differentially expressed miRNAs between MM and PCL a trend might be 
identified in relationship with normal donors. Interestingly, for 56/83 (approximately 
70%) miRNAs differentially expressed between pPCL and MM, the trend of expression 
(increasing or decreasing) from healthy controls, through MM, to pPCL was 
significantly maintained (Jonckheere-Terpstra test, P < 0.005, (Table 7 and Figure 15 
C). 
Oncogenic role of miR-21 in malignant plasma cells 
The putative oncogenic role of some miRNAs over-expressed in pPCL, suggested by 
the functional enrichment analysis and by consistent trends of expression from normal 
plasma cells to pPCL, was directly demonstrated for miR-21 by in vitro experiments 
performed in collaboration with the group headed by Prof.Tassone at the University of 
Catanzaro. First of all, we evaluated miR-21 expression in HMCLs, and found variable 
levels of expression; notably, we found > 3 fold increase in miR-21 expression when 
the IL-6-dependent INA-6 cells were cultured adherent to hBMSCs. 
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To study the anti-MM activity of miR-21 inhibition, we transfected MM cell lines with 
miR-21 inhibitors. By trypan blue exclusion cell count and BrdU proliferation assay, 
we found significantly decreased cell growth in MM cell lines expressing high miR-21 
levels (KMS26, U266 and OPM2) (Figure 16 A and B). In these cells, we also 
observed reduction of cell survival by MTT assay (Figure 16 C). Conversely, miR-21 
inhibitors did not affect cell proliferation or survival of MM cell lines with low miR-21 
expression (NCI-H929, MM1S, RPMI-8226) (data not shown). 
Figure 16 | Effects of ectopic expression of miR-21 inhibitors in MM cell lines. (A) Trypan blue 
exclusion growth curves were generated from KMS26, U266 and OPM2 cells transfected with miR-21 
inhibitors or scrambled controls (miR-NC inhibitors). (B) BrdU proliferation assay was performed in 
KMS26, U266 and OPM2 cells 48h after transfection with miR-21 inhibitors or scrambled controls. (C) 
MTT survival assay was performed in KMS26, U266 and OPM2 cells 48h after transfection with miR-21 
inhibitors or scrambled controls. Averaged values ± SD of three independent experiments are plotted. P 
values were obtained using two-tailed t test. 
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BMSCs in the human BM milieu strongly support survival and proliferation of MM 
cells. Since miR-21 expression in INA-6 cell line was significantly enhanced by 
adherence of cells to hBMSCs, we next evaluated whether miR-21 inhibition could 
overcome the supportive effects of the BM microenvironment. To this aim, we 
evaluated the anti-tumor activity of miR-21 inhibition in a context closely resembling 
the intramedullary stage of MM. Specifically, we cultured IL-6-dependent MM cell line 
INA-6 adherent to hBMSCs and enforced the expression of miR-21 inhibitors in both 
cell types. As shown in Figure 17 A, miR-21 inhibition affected viability of MM cells 
to a similar extent as does hBMSCs deprivation. MiR-21 inhibition was also observed 
in INA-6 cells cultured in an IL-6-enriched culture medium (Figure 17 A). We 
wondered whether this effect was due to miR-21 inhibition directly in INA-6 cells, in 
hBMSCs, or in both. Therefore, we investigated the effects of miR-21 inhibition in 
INA-6 cells co-cultured with non transfected hBMSCs, and found that the anti-tumor 
effect was similar to that obtained when miR-21 inhibition was performed in both cell 
types (Figure 17 B). In contrast, no effects were observed when miR-21 was inhibited 
only in hBMSCs adhering to INA-6 cells (Figure 17 B). From these findings, we 
conclude that miR-21 inhibitors abrogate the supporting activity of hBMSC on MM cell 
lines. 
Figure 17 | MiR-21 inhibition antagonizes pro-survival effect of BM milieu. (A) MTT assay of INA-6 
cells cultured adherent to hBMSCs, in IL-6-enriched culture medium, or in IL-6-free culture medium. 
The assay was performed 48 hours after transfection of co-cultured cells with miR-21 inhibitors or 
scrambled controls (miR-NC inhibitors). (B) MTT assay of INA-6 cells cultured with hBMSCs was 
performed 48 hours after either INA-6 cells or hBMSCs were independently transfected with miR-21 
inhibitors or scrambled controls.  
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Part III 
Integrative miRNA/GEP analysis for miRNA target 
identification 
To gain further insights into the function of differentially expressed miRNAs between 
pPCL and MM cases, we took advantage of the availability of gene expression data for 
all 18 pPCL cases and 36 of the 39 MM patients analyzed for miRNA expression for 
performing an integrative analysis of miRNA and gene expression data combined with 
miRNA target prediction. This approach can only identify putative target genes whose 
regulation involves mRNA degradation rather than translation repression. In particular, 
we assessed the correlation between the expression data of all possible miRNA-gene 
pairs in 18 pPCL and 36 MM cases, and for each significantly anti-correlated pair we 
verified the existence of a predicted targeting relationship by 9 computational 
algorithms, then selecting those genes predicted as targets by at least 5 miRNA target 
prediction programs. In this way, seventy-four statistically significant negative 
correlations involving differentially expressed miRNAs and putative target genes were 
computed (Table 8). These targeting relationships were exerted by 24 distinct miRNAs 
(11 down- and 13 up-regulated) on 69 different genes, and in 5 cases one gene was 
anti-correlated with more than one miRNA. All the 74 predicted interactions are 
reported in Figure 18. Several anti-correlated genes were involved in biological 
functions related to the regulation of cellular component organization according to the 
DAVID functional annotation tool. Interestingly, most of these anti-correlated genes 
were differentially expressed between these pPCL and MM samples (as highlighted in 
Table 8).  
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Figure 18 | MiRNA-putative target regulatory relations supported by expression data. Up-regulated 
miRNAs in pPCL are indicated in red, down-regulated in light blue.
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Table 8 | Negative correlations involving differentially expressed miRNAs between pPCL and MM patients and putative target transcripts. 
 
59 
 
Target validation assays 
We then performed a target validation assay for some of the anti-correlations found in 
our analysis. To this aim, we focused on genes that, based on previous literature data, 
might have potential involvement in plasma cell dyscrasia, such as ACVR1/miR-301a 
and miR-301b (Figure 19 A and B), SULF2/miR-330-3p and TNFAIP3/let-7a. 
Interestingly, luciferase expression from the 3’UTR sequence of ACVR1 was 
suppressed by almost 20% (one-sided Student’s t-test, P = 0.002) in 293T cells co-
transfected with pACVR1 3’UTR, miR-301a and miR-301b (Figure 19 C), while the 
same approach did not confirm the putative SULF2/miR-330-3p and TNFAIP3/let-7a 
anti-correlations (data not shown). 
Figure 19 | MiRNA/target anticorrelation in MM. Significant negative correlation of ACVR1 mRNA 
with (A) miR-301a and (B) miR-301b levels. The spots represent mature miRNA expression (scale on 
right-sided vertical axis), and the grey bars represent target gene expression (scale on left-sided vertical 
axis) in the dataset of 36 MM and 18 pPCL patients. Horizontal axis: patient samples ordered according 
to increasing miRNA expression. (C) Luciferase assay showing decreased luciferase activity in cells 
transfected with pre-miR-301a and pre-miR-301b compared to cells transfected with pre-miR negative 
control. All experiments were performed in triplicate. Results were plotted as relative luciferase activity 
mean ± standard deviation. 
 
ACVR1 codes for the receptor of bone morphogenetic protein 4 (BMP4), and was 
recently reported to be increased in MM samples compared with normal controls and 
correlated with the level of plasma cell infiltration (Grcevic et al., 2010). These data 
provide an important basis for further validation experiments, necessary to determine 
the actual occurrence of putative targeting relationships and thus the final impact of 
miRNA deregulation on gene expression. 
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Part IV 
Clinical relevance of miRNA profiles in pPCL 
Finally, we evaluated miRNA expression in the context of clinical outcome of the 
prospective and homogeneously treated series of pPCL patients, including all cases 
except one, lost at follow-up. Specifically, we aimed to assess whether the occurrence 
of a miRNA signature at diagnosis might be associated with response to treatment, 
PFS, or OS. Considering the primary end-point of our study, we investigated the 
dataset using stringent supervised analysis seeking differentially expressed miRNAs in 
patients who failed to respond to frontline, planned 4-cycle therapy of 
lenalidomide/dexamethasone (NR). The analysis led to the identification of four mature 
miRNAs (miR-106b, miR-497, miR-181b, and miR-181a*) up-regulated in non-
responder patients compared to responder ones, namely those with complete response 
(CR), very good partial response (VGPR) and partial response (PR) (Figure 20). No 
specific differentially expressed miRNA could be evidenced when PR, VGPR and CR 
were considered as different classes of response. This finding will helpfully integrate 
results on efficacy and side effects of the first-line treatment of 
lenalidomide/dexamethasone in pPCL (Musto et al., manuscript in preparation). 
Figure 20 | MiRNAs associated with response to treatment in pPCL. (A) Heatmap of the four 
differentially expressed miRNAs identified by supervised analysis of pPCL patients stratified according 
to response rate (NR versus PR/VGPR/CR). (B) List of the four differentially expressed miRNAs 
identified by stringent supervised analysis between non-responder and responder patients (SAM, q-value 
= 0). MiRNAs are ordered according to the SAM score (d); the numerator and denominator of the 
relative formula are also shown, together with the fold-change and q-value. 
 
Furthermore, we assessed the relationship between each of the most variable miRNAs 
across the dataset (i.e. those whose average ratio of the expression values on the mean 
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was higher than 1.5) and either PFS or OS, representing the secondary end-points of the 
prospective protocol. Of the 114 most variable miRNAs, two reached a significant 
correlation (P < 0.01) with PFS (miR-22 and miR-146a, Figure 21 A and B), allowing 
the division of samples into two groups with different outcome. 
Figure 21 | MiRNAs associated with PFS and OS in pPCL. Kaplan–Meier estimated progression-free 
survival curves for miR-22 (A) and miR-146a (B), and overall survival curves for miR-92a (C) and miR-
330-3p (D) in pPCL cohorts. The samples have been stratified into two groups (dashed line: high 
expression; solid line: low expression) according to the thresholds on sorted expression profiles that led 
to the highest hazard ratio. 
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The expression of the two miRNAs retained independency from all the molecular 
characteristics available, as well as from age, sex, LDH levels, renal function and 
hematologic parameters (Table 9 A and B). As regards OS, two miRNAs reached a 
significant correlation with the clinical endpoint (miR-92a and miR-330-3p) (Figure 21 
C and D). In multivariate analyses, none of the two miRNAs were independent of 
patients being subjected to ASCT, indicating that this therapeutic approach points 
definitively towards a more favorable outcome (Table 9 C and D). It is worth 
mentioning that none of the cytogenetic aberrations was associated per se with PFS and 
OS (Mosca et al., 2013). In particular, we evaluated whether the prevalence of t(4;14), 
t(11;14), MAF-related translocations, 1p loss, 1q gain, del(13q14), and del(17p13) 
correlated with the secondary endpoints of the clinical trial, namely OS and PFS. 
However, none of the considered cytogenetic aberrations was significantly associated 
neither with OS nor with PFS (data not shown).  
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Table 9. Multivariate analysis comparing each of the four miRNA-models (A: miR-22, B: 
miR-146a, C: miR-92a, D: miR-330-3p) with biological and molecular variables in pPCL 
series. The model was available for all covariates with the exception of the cases (“nd”) in 
which the occurrence of covariate was radically inversely correlated with being part of the 
high-risk group (namely, for ASCT in OS analysis) or whenever the configuration of survival 
data versus covariates value in any group (i.e. the distribution of events) prevented the 
calculation of hazard ratio model. 
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Discussion 
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In this study we reported a miRNA expression profiling analysis of a series of pPCL 
patients included in a prospective clinical trial aimed at exploring efficacy and safety of 
lenalidomide and dexamethasone combination as first line therapy in previously 
untreated patients. At the same time, pPCL samples included in the trial and for whom 
material was available were subjected to FISH, genotyping and GEP analyses. MiRNA 
expression patterns were evaluated in relation to the most recurrent chromosomal 
abnormalities and in comparison with a representative series of MM patients, 
identifying miRNAs that may contribute to explain the aggressive phenotype of pPCL, 
based on their known or inferred functions from integrative analysis of miRNA and 
GEP data or on in vitro functional analyses in HMCLs. Finally, we identified miRNAs 
putatively involved in pPCL clinical outcome. 
Chromosomal alterations and miRNA expression profiling in 
pPCL patients 
Existing studies have so far demonstrated that pPCL shows the main molecular 
characteristics of other plasma cell dyscrasias (e.g., IGH@ translocations or 13q and 
17p deletions). As regards chromosomal translocations, those involving the 14q32 
locus and the CCND1, FGFR3/MMSET, or MAF partner genes have been reported 
occurring in the majority of primary, as well as in secondary PCLs. Herein, we 
identified the occurrence of IGH@ translocations in ~87% of pPCL cases; such an 
incidence overlaps with those reported by several authors (Avet-Loiseau et al., 2001a; 
Avet-Loiseau et al., 2012; Chang et al., 2009; Chiecchio et al., 2009; Tiedemann et al., 
2008), confirming the widely accepted notion that IGH@ translocations are almost an 
ubiquitous event in PCL. However, the frequency of the different types of partner loci 
still remains controversial and this is probably related to the heterogeneous series 
investigated or geographical factors, as already suggested by other Authors (Tiedemann 
et al., 2008). Specifically, in our study the frequency of the t(11;14) was approximately 
40%, quite similar to that reported by some authors (Avet-Loiseau et al., 2001a; 
Chiecchio et al., 2009), but lower than that reported by others (Chang et al., 2009; 
Tiedemann et al., 2008). As regards IGH@ translocations involving MAF gene, we 
found higher frequency (30.5%) than those reported in previous works, where 
incidence in pPCL was approximately 10–17% (Avet-Loiseau et al., 2001a; Avet-
Loiseau et al., 2012) if not absent (Tiedemann et al., 2008), and almost identical to that 
reported by Chiecchio et al. (Chiecchio et al., 2009). Finally, we found a 13% 
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incidence of t(4;14), quite similar to an earlier report (Avet-Loiseau et al., 2001a) but 
different from other studies in which it was found at higher frequency (21–25%) (Avet-
Loiseau et al., 2012; Chang et al., 2009) or completely absent (Chiecchio et al., 2009; 
Tiedemann et al., 2008). Concerning the impact of chromosomal alterations on miRNA 
expression, IGH@ translocations seemed to be less associated with distinct miRNAs 
profiles compared to what we observed in MM patients, although some miRNAs 
deregulated in a similar manner have emerged: apart from let-7e, over-expressed in 
t(4;14) pPCL cases, other miRNAs were found up-regulated (although at lower levels 
of statistical significance) in this molecular group of pPCL in agreement with what 
found in MM cases, i.e. miR-125a-5p, miR-221, miR-221*, and miR-222; likewise, also 
miR-150 was up-regulated in MAF-translocated pPCL cases (FDR = 10%). An 
interesting similarity was highlihted between miRNA expression profiles of pPCL and 
MM TC5 patients, suggesting further investigations on whether pPCL might share 
some clinico-biological features with MAF-translocated MM. 
Regarding numerical chromosomal alterations, we confirmed the remarkable frequency 
of del(13q) in pPCL which is higher than that reported in MM (Walker et al., 2010). 
We found this lesion in 17/23 (74%) patients; based on SNP-array data we confirmed 
the loss of the entire chromosome in the majority of cases, with the exception of three 
pPCLs showing relatively large interstitial deletions encompassing the 13q14 region. 
Interestingly, several deregulated miRNAs in association with alterations involving the 
corresponding genomic loci were mapped to chromosome 13. In particular, the down-
regulation of miR-15a in patients carrying chromosome 13 deletion is of particular 
importance given the frequency of this genomic lesion in pPCL and the experimental 
evidence that it may acts as a tumor suppressor miR in malignant plasma cells (Hao et 
al., 2011a; Roccaro et al., 2009). Roccaro et al. indeed provided the first evidence of 
the functional role of miR-15a and miR-16 in MM by showing that the two miRNAs 
regulate the proliferation and growth of HMCLs in vitro and in vivo by inhibiting a 
number of molecular pathways, such as those involving AKT3, ribosomal protein S6, 
MAP kinases, and the NF-κB-activator MAP3K7IP3 (Roccaro et al., 2009). 
Furthermore, miR-15a and miR-16 inhibit MM cell-triggered endothelial cell growth 
and capillary formation in vitro and in vivo, and exert their anti-MM activity of 
inhibiting migration and growth of MM cells even in the context of the BM milieu, thus 
overcoming the growth advantage normally conferred by BM stromal cells. A possible 
explanation of this finding resides in that the suppression of miR-15a/16 expression 
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(possibly mediated by IL-6 secretion) represents one of the mechanisms through which 
BM stromal cells provide survival support to MM cells. Interestingly, Hao et al. 
reported that melphalan and bortezomib treatment up-regulated miR-15a/16 expression 
in MM cells, whereas the interaction of MM cells with BMSCs inhibited miR-15a/16 
expression and suppressed apoptosis of MM cells induced by cytotoxic agents (Hao et 
al., 2011a; Hao et al., 2011b). These data strongly suggest the tumor suppressor 
activity of miR-15a and miR-16, although their role in disease development in primary 
MM patients and the impact of chromosome 13 deletion on their expression remain 
controversial (Table 10): in fact, the specific down-regulation of miR-15a and miR-16 
(regardless of the status of chromosome 13) was the starting point for Roccaro’s study 
of their functional role in MM (Roccaro et al., 2009), but Pichiorri et al. found that 
miR-15a (as well as other miRNAs mapped on 13q) was up-regulated in MM PCs 
versus healthy PCs (Pichiorri et al., 2008). 
Table 10 | MiR-15a and miR-16 expression in MM (adapted from Lionetti et al., Current 
Cancer Drug Targets 2012). 
Reference Platform Result 
Pichiorri et al., 
PNAS 2008 
Academic miRNA 
microarray miR-15a up-regulated in MM versus healthy PCs. 
Roccaro et al., 
Blood 2009 
Liquid phase luminex 
microbead miRNA 
profiling 
miR-15a/16 down-regulated in relapsed/refractory MM 
versus healthy PCs (absent in MM with del(13) and 
down-regulated in those without deletion). 
Lionetti et al., 
Genes Chromosomes 
Cancer 2009 
Agilent miRNA 
microarray V1 
miR-15a expression correlates with 
DNA copy number in HMCLs. 
Lionetti et al., 
Blood 2009 
Agilent miRNA 
microarray V2 
miR-15a/16 expression unaffected by 
chromosome 13 status in MM. 
Gutierrez et al., 
Leukemia 2010 
Applied Biosystems 
TaqMan 
low-density arrays 
miR-15a down-regulated in MM with RB deletion 
versus other MM or healthy PCs. 
Corthals et al., 
Leuk. Res 2010 
Applied Biosystems 
TaqMan 
miRNA assays 
miR-15a/16 up-regulated in MM than healthy PCs 
independently of chromosome 13 status. 
Zhou et al., 
PNAS 2010 
Agilent miRNA 
microarray V1 
miR-15a/16 marginally up-regulated in MM 
than healthy PCs. 
Chi et al., 
Biology Direct 2011 µRNA microarray 
down-regulation of both miR-15a/16 
in del(13) cases. 
Our group found a significant correlation between the expression of miR-15a and 
alterations of the corresponding DNA locus in HMCLs (probably due to miRNA over-
expression in aneuploid cell lines with more than two copies of chromosome 13) 
(Lionetti et al., 2009a) but not in primary MM tumors, in which only the expression of 
miR-17 and miR-20a (13q31) was reduced in cases with 13q deletion (Lionetti et al., 
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2009b). Other Authors have reported varying levels of miR-15a/16 (Corthals et al., 
2010) as well as of miR-17∼92 (Chen et al., 2011) expression in MM patients, 
regardless of chromosome 13 status. Finally, Gutierrez et al. found that, like miR-19a, 
miR-19b and miR-20a, miR-15a was down-regulated in the samples of patients carrying 
the RB deletion alone in comparison with the normal PC samples or the samples of MM 
patients without this abnormality (Gutierrez et al., 2010), and Chi et al. reported the 
down-regulation of both miR-15a/16 and miR-17∼92 cluster in del(13) cases (Chi et al., 
2011). 
As regards miR-17∼92, copy number of chromosome 13 (although correlated with the 
expression of some of the miRNAs belonging to the cluster, i.e. miR-19a, miR-20a, 
miR-20a* and miR-92a) was unlikely the only factor affecting its expression in our 
pPCL cohort; in fact we found that some miRNAs belonging to the cluster resulted 
significantly over-expressed in pPCL compared to MM cases independently of their 
CN status. This appears to be in line with the reported evidence of the oncogenic 
potential of this miRNA cluster, as also specifically demonstrated in the context of 
myeloma cells (Chen et al., 2011; Pichiorri et al., 2008). 
Our study confirmed the increased frequency of TP53 deletion in comparison with that 
reported in MM. Furthermore, we identified four TP53-mutated cases, three of which 
associated with a gene deletion. Therefore, ∼13% of cases in our series showed biallelic 
inactivation of TP53, similarly to that reported by other Authors (Chiecchio et al., 
2009; Tiedemann et al., 2008). Interestingly, our data represent the first evidence in the 
context of plasma cell dyscrasias of a decreased expression of miR-34a in association 
with TP53 abnormalities, as already found in other tumors, such as CLL (Mraz et al., 
2009): importantly, enforced expression of miR-34a in MM cell lines indicated the this 
miRNA exerts anti-myeloma activity in vitro. The high sensitivity of TP53-mutated 
MM cells is of interest, as TP53 inactivation is a rare event at diagnosis, but it becomes 
common when intramedullary MM progresses to a drug-resistant and more aggressive 
phenotype, as well as in pPCL and sPCL, suggesting that the "biologically end-stage" 
disease might benefit from therapies restoring the TP53 function through miR-34a 
enforcement. Furthermore, SNP-array data showed the loss of a large part of 17p in all 
but one cases tested positive del(17p); this finding is reminiscent of what was reported 
in CLL by our previous study (Fabris et al., 2008) suggesting that other important 
tumor suppressor genes/miRNAs located in this region may contribute to the tumor 
development and expansion in pPCL. In this regard, one of the several down-regulated 
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miRNAs in pPCL in association with the loss of the corresponding genomic loci that 
have already been linked to cancer as having a tumor suppressor role was miR-22 
(Takata et al., 2011; Xiong, 2012), precisely mapped at chromosome 17p13.3 and 
whose down-regulation was found associated with shorter progression free survival in 
our pPCL cohort, as will be discussed in more detail later. Other down-regulated 
putative tumor suppressor miRNAs identified were miR-331-3p (12q22) (Guo et al., 
2010b), miR-342-3p (14q32.2) (Wang et al., 2011a) and miR-30e and miR-30c (Wu et 
al., 2009), these latter localized at chromosome 1p34.2, another hot-spot altered region 
as emerged from the DNA genome-wide analysis; overall, indeed, the incidence of 1p 
loss and 1q gain was ~40 and 50%, respectively, which is only slightly higher than that 
reported in MM by us and several other groups (Agnelli et al., 2009; Fabris et al., 
2007; Hanamura et al., 2006; Sawyer, 2011). 
 
 
MiRNA expression profiling of pPCL and MM patients 
The clustering of samples based on the expression of the 76 most variable miRNAs 
indicated a significant grouping of pPCL and MM cases in two main branches, 
respectively. The differences in miRNA expression profiles of MM and pPCL 
highlighted by the unsupervised analysis were confirmed by direct comparison of these 
clinical entities: pPCL and MM patients were found to differentially express 83 
miRNAs, roughly half of which over-expressed in one group with respect to the other. 
It is worth noting that the expression of approximately 70% of these miRNAs 
maintained a statistically significant trend when considering normal donors, reinforcing 
the hypothesis that the deregulation of these miRNAs might be compatible with the 
“strength” of neoplastic transformation. Furthermore, up-regulated miRNAs in pPCL 
were enriched in “onco-miRNAs”, such as miR-21, miR-155 (Faraoni et al., 2009; Tili 
et al., 2009) and miRNAs belonging to the paralogous clusters miR-17∼92 and miR-
106a∼363 (miR-18a, miR-19a, miR-18b and miR-20b). In particular, miR-21 was found 
over-expressed in the majority of cancer types analyzed, acting as a cancer biomarker. 
Its relevance in MM was first suggested by Loffler et al., who demonstrated that miR-
21 transcription is controlled by IL-6 through a mechanism involving STAT3 and that 
its ectopic expression gives independence from the IL-6-growth stimulus (Loffler et al., 
2007). More recently, miR-21 inhibition was shown to have a synergistic anti-MM 
effect with dexamethasone or doxorubucin (Wang et al., 2011b), and our preliminary 
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data indicated that targeting miR-21 inhibits in vitro MM cell growth. Importantly, 
miR-21 expression in MM cells was significantly enhanced by adherence of cells to 
hBMSCs, and anti-MM activity of miR-21 inhibitors was exerted also in the context of 
bone marrow milieu, antagonizing the BMSCs protective role on MM cells. Globally, 
based on these findings, the increased expression of miR-21 in pPCL compared with 
MM patients seems to be closely related to the independence of the leukemic cells from 
the bone marrow microenvironment. MiR-17∼92 functions pleiotropically during both 
normal development and malignant transformation to promote proliferation, inhibit 
differentiation, augment angiogenesis and sustain cell survival, and its over-expression 
has been observed in multiple tumor types (Olive et al., 2010). In addition to the initial 
evidence of its important role in MM (Pichiorri et al., 2008), a recent study 
demonstrated that MYC may inhibit MM cell apoptosis by activating the miR-17∼92 
cluster, leading to the down-modulation of the pro-apoptotic protein BIM. Interestingly, 
MM patients with higher expression of miR-17, miR-20 or miR-92 had shorter PFS 
(Chen et al., 2011). On the contrary, several miRNAs with lower expression in pPCL 
compared with MM are thought to play a tumor suppressor role in various tumor types, 
such as miR-663 (Pan et al., 2010; Tili et al., 2010), miR-193b (Xu et al., 2010; Chen et 
al., 2010; Li et al., 2009a), miR-126 (Meister and Schmidt, 2010) and let-7a (Boyerinas 
et al., 2010). Interestingly, let-7a has been reported to be repressed by, and in turn 
repress, MYC (Boyerinas et al., 2010), and to be involved in the IL-6 pathway (Meng 
et al., 2007; Iliopoulos et al., 2009). Notably, high expression levels of miR-142-5p, 
miR-21, miR-125b, miR-103, miR-99a, miR-26b or members of the cluster miR-17∼92, 
up-regulated in pPCL, were found to be associated with GEP-defined high risk score in 
MM patients (Zhou et al., 2010). 
Several over-expressed miRNAs in pPCL also seem to be related to immune response, 
particularly the above mentioned miR-17∼92 cluster (Olive et al., 2010), miR-155 
(Faraoni et al., 2009; Tili et al., 2009) and miR-21 (Iliopoulos et al., 2010; Sheedy et 
al., 2010). Specifically, miR-155 and miR-21, known to share an important role in 
tumorigenesis, may represent important links between cancer and inflammation, likely 
through their relationship with the NF-κB pathway, known to promote their 
transcription (Ma et al., 2011). Furthermore, miR-301a, another up-regulated miRNA 
in pPCL, has been demonstrated to be activated by NF-κB (Ma et al., 2011). Both miR-
21, miR-155 and miR-301a in turn affect the NF-κB pathway, leading to its activation 
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or inhibition, in part dependent on the cellular context (Li et al., 2009b; Ma et al., 
2011) (Figure 22). 
 
Figure 22 | Involvement in NF-κB pathway of some deregulated miRNAs in pPCL. MiR-301a, miR-
155 and miR-21, up-regulated in pPCL, are transcriptionally activated by NF-κB pathway and in turn 
affect it. By controlling the expression of IKK-epsilon and possibly IKK-beta, miR-155 limits NF-κB 
activation, constituting a negative feed-back loop (Ma et al., 2011); on the contrary, miR-301a was 
reported in solid tumors to down-regulate NF-κB-repressing factor (Nkrf), thus creating a positive feed-
back loop for persistent NF-κB activation (Ma et al., 2011). Experimental evidence in different cellular 
contexts supports either miR-21 activating or inhibitory effect on NF-κB pathway (Li et al., 2009b; Ma et 
al., 2011). MiR-223, significantly down-regulated in pPCL, was shown in macrophages to negatively 
affect the non-canonical NF-κB pathway through the targeting of IKK-alpha (Ma et al., 2011). 
 
Notably, gene expression profiling analysis of a dataset of pPCL and MM samples 
including most of the patients analyzed for miRNA expression profiling identified 
several differentially expressed NF-κB pathway associated genes between MM and 
pPCL (Todoerti. et al., submitted). The repression of a member of NF-κB pathway, 
IKK-alpha, has been reported also for miR-223 (Ma et al., 2011), a hematopoietic 
specific miRNA involved in several types of leukemia and solid tumors. Mir-223 was 
down-regulated in our pPCL series and nonetheless its absence has recently been 
observed in extramedullary plasmacytoma (Yu et al., 2011); it was also found to 
suppress cell proliferation by targeting IGF-1R (Jia et al., 2011), involved in motility 
and invasiveness control in MM cells. Overall, these findings strongly suggest an 
important role for deregulated miRNAs involved in NF-κB pathway in pPCL and may 
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have implications for future therapeutic approaches, given, for example, the efficacy of 
bortezomib, a drug which interferes with NF-κB pathway, in pPCL patients. 
 
 
Clinical relevance of miRNA profiles in pPCL 
We investigated whether specific miRNA signatures could be associated with the 
response rate after four cycles of therapy, which represented the primary endpoint of 
the study. Interestingly, a four-miRNA signature (miR-106b, miR-181a*, miR-181b and 
miR-497) was found significantly up-regulated in non-responding cases. Of note, both 
miR-106b and miR-181b were reported to be up-regulated in MM cells compared to 
healthy PCs (Pichiorri et al., 2008; Roccaro et al., 2009) and associated with increased 
MM GEP-defined risk score (Zhou et al., 2010) and, interestingly, miR-181a* was one 
of up-regulated miRNAs in pPCL versus MM cases; this finding makes this miRNA a 
potential therapeutic target in pPCL. 
Moreover, a further contribution to clinical prognostication was represented by 
identification of four additional miRNAs, the expression of which was associated with 
pPCL cases with a worse outcome: in particular, the down-regulation of miR-22 and the 
up-regulation miR-146a implied shorter PFS, while down-regulation of miR-330-3p 
and up-regulation of miR-92a were accompanied by lower OS. Interestingly, miR-146a 
deregulation has been associated with the pathogenesis of several human diseases, 
including solid tumors and hematopoietic malignancies, and this miRNA is thought to 
play an important role in the regulation of innate immune and inflammatory responses 
through a negative feedback pathway involving NF-κB (Labbaye and Testa, 2012; Ma 
et al., 2011). This finding, together with previously described interactions between 
deregulated miRNAs and NF-κB pathway, warrants further investigations to clarify 
whether the miRNAs/NF-κB network may have a role in pPCL outcome. Notably, in 
our series miR-22 was found significantly down-regulated in accordance with allelic 
loss of its residing locus at 17p13.3; however, TP53 deletion per se was not associated 
with PFS (data not shown), thus suggesting that factors other than deletion of 17p may 
affect miR-22 expression. Mir-22 has already been linked to cancer through its putative 
tumor suppressor role; it is activated by TP53, suppresses NF-κB activity and is 
thought to repress the MYC binding proteins MAX and MYCBP and to be inhibited by 
MYC itself (Takata et al., 2011; Xiong, 2012). As regards miR-92a, it is a member of 
the above mentioned cluster miR-17∼92, and its up-regulation in MM has been reported 
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in comparison with normal PCs (Pichiorri et al., 2008), in relation to increased MM 
GEP-defined risk score (Zhou et al., 2010), and in association with shorter PFS (Chen 
et al., 2011). Considering that pPCL represents a high-risk clinical entity per se, 
biological information at diagnosis could be helpful to guide clinicians in therapeutic 
decisions; therefore, larger prospective series of patients would be required to better 
elucidate the clinical relevance of miRNAs in pPCLs. 
Overall, our study represents the first attempt to investigate the involvement of 
miRNAs in pPCL, the most aggressive form of plasma cell dyscrasia, and our data may 
contribute towards the development of functional approaches to analyze the activity of 
deregulated miRNAs and their possible role as novel therapeutic targets.  
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